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ABSTRACT
Health Literacy, Cognitive Impairment, and Medication Adherence in Veterans with
Heart Failure
Background: Heart failure (HF) affects 5.8 million people in the United States, costly in 
terms of patient mortality and morbidity as well as healthcare dollars. One important 
manifestation of poor HF outcomes is the excessive admission-readmission cycle. Non­
adherence to medication is responsible for the majority of HF readmissions. Identification 
and intervention for key factors contributing to poor medication adherence is critical to 
improving outcomes. Two such factors prevalent in persons with HF are cognitive 
impairment (Cl) and poor health literacy (HL). There is a paucity of tested interventions 
designed to improve medication adherence by addressing underlying Cl or HL. A recent 
study tested a pictorial medication sheet to improve medication adherence in veterans 
with HF and Cl, however no information on HL was collected. This new study examines 
what mediating effects HL may have played in the adherence scores of subjects in the 
completed study.
Study Aims:
Aim 1. Describe the level of HL in the study population.
Aim 2. Determine the strength and direction of the relationships between reading HL and 
numeracy HL and selected clinical and demographic variables in the study population.
Aim 3. Determine the direct and indirect effects that reading HL and numeracy HL and 
other key variables (including the intervention) have upon medication adherence in
cognitively impaired veteran outpatients with HF based on prior data from an 
interventional study testing a pictorial medication sheet to improve medication 
adherence.
Study Design
A retrospective, correlational, cross-sectional design was employed to analyze HL scores 
from medical records with data from the completed study using conventional statistics 
and structural equation modeling.
Results: 27 subjects with a mean age of 65.3 years (SD 8.2, range 45-80) had evaluable 
data. HL was less than adequate in 19% of the sample. HL scores were strongly 
correlated with cognition. HL did not significantly affect relationships between study 
covariates (cognition scores, depression, number of medications) and medication 
adherence.
Conclusions and Significance: HL scores were associated with cognitive function 
scores. More research is needed to evaluate the prevalence and effect of poor HL in 
veterans with HF upon adherence.
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Chapter 1: Introduction
Heart failure (HF) is a complex, chronic medical condition that affects 5.8 million 
people in the United States, contributing significantly to increased morbidity, mortality, 
healthcare expenditures, and decreased quality of life (Lindenfeld et al., 2010; Lloyd- 
Jones et al., 2010). This negative impact of HF is projected to escalate as the American 
population ages, and is of particular importance to the Veterans’ Health Care System 
(VA), the largest integrated healthcare system in the United States (Heidenreich, 2011; 
Population Resource Center, 2011). Large clinical trials have demonstrated the success of 
pharmacologic regimens and lifestyle strategies in improving patient outcomes and have 
resulted in the development of consensus guidelines (Lindenfeld et al., 2010). However, 
HF patients tend to be older with multiple comorbidities and may find it difficult to 
follow these often-complex regimens, thereby losing the benefits of evidence-based care 
(Heidenreich, 2004; Murray et al., 2007). One particularly important manifestation of 
poor HF outcomes is the excessive admission-readmission cycle; in the VA system 20% 
of HF patients are readmitted within 30 days (Heidenreich, 2011). Medication non­
adherence is common in persons with HF, and has been shown to be responsible for the 
majority of readmissions for HF in the United States (Albert, 2008; Esposito, Bagchi, 
Verdier, Bencio, & Kim, 2009; Ho, Bryson, & Rumsfeld, 2009; Munger, Van Tassell, & 
LaFleur, 2007; Murray, et al., 2009). Thus identification of, and intervention for, key 
factors contributing to poor medication adherence has become a primary goal for 




Adherence is a complex issue and depends on multiple patient and healthcare- 
related factors. The World Health Organization’s Multidimensional Adherence Model 
classifies predictors of poor adherence into five broad domains: socio-economic status, 
type of healthcare system, prescribed therapy, condition being treated, and individual 
patient-related factors (Sabate, 2003). However, this model explained less than 20% of 
poor medication adherence in HF patients, emphasizing the need to identify other 
contributors to non-adherence in this population (van der Wal & Jaarsma, 2008; Wu, 
Moser, Chung, & Lennie, 2008). One frequently overlooked factor that may influence all 
of these domains is the presence of cognitive impairment (Cl). Indeed, a recent study in 
veterans with HF demonstrated a high prevalence (58%, n=251) of clinically 
unrecognized Cl that was significantly associated with poorer medication adherence 
(Hawkins et al., 2012).
Another factor associated with adherence is poor health literacy (HL). In 
America, low health literacy is a highly prevalent and clinically under-recognized 
problem that directly impacts patient’s self care skills (Morrow et al., 2006). Poor HL 
predicts poor medication adherence, but little is known about the prevalence of poor HL 
in veterans with HF, or the effect of HL on medication adherence in cognitively impaired 
outpatients with HF (Evangelista et al., 2010; Moser & Watkins, 2008).
Interventions to Improve Adherence
There is a general lack of awareness on the part of providers in regards to the 
prevalence of Cl and poor HL in their patients, and the contribution of these factors to
poor medication adherence (Cameron et al., 2010). Interventions that rely on traditional 
models of patient education to improve adherence are thus likely to fail in this at-risk 
population, and there is a paucity of tested interventions that improve outcomes by 
improving medication adherence (Wu, Corley, Lennie, & Moser, 2012). Novel 
interventions targeted at key factors contributing to non-adherence are urgently needed.
To address this gap, a pilot study (TARGET) was designed utilizing two 
interventions addressing Cl as the underlying cause of medication non-adherence. The 
TARGET study enrolled subjects with known Cl from an outpatient veteran HF clinic 
and tested the effectiveness of an intervention to improve medication adherence 
(Hawkins, Firek & Silvet, 2012). The intervention, a pictorial medication sheet, was 
designed to address memory problems from underlying cognitive impairment. The 
primary outcome, medication adherence, was measured from sequential direct 30-day pill 
counts, using subjects as their own controls. A major limitation in the TARGET study is 
that no information on HL was collected. HL may actually mediate the relationship 
between key independent variables (including the intervention) and medication adherence 
in this study.
Purpose of Study
The purpose of this dissertation research study was to estimate the causal 
relationships between HL (included in existing outpatient medical records), the 
intervention, other key variables, and medication adherence in a sample of cognitively 
impaired outpatient veterans with HF who participated in an interventional pilot study
testing a pictorial medication sheet and alarmed pill box to improve medication 
adherence.
Using previously-collected data from the TARGET pilot study and the existing 
outpatient medical records of the TARGET participants, a retrospective, correlational, 
cross-sectional study design using secondary data was used to answer the study research 
question: What are the direct and indirect effects that HL and other key variables 
(including the intervention) had upon medication adherence in cognitively impaired 
veterans with HF?
Research Alms
The specific aims of the study were to:
Aim 1. Describe the level of HL in the study population.
Aim 2. Determine the strength and direction of the relationships between reading HL and 
numeracy HL and selected clinical and demographic variables in the study population.
Aim 3. Determine the direct and indirect effects that reading HL and numeracy HL and 
other key variables (including the intervention) had upon medication adherence in 
cognitively impaired veteran outpatients with HF based on prior data from an 
interventional study testing a pictorial medication sheet and alarmed pillbox to improve 
medication adherence.
Summary
Heart failure is an epidemic facing the American healthcare system, and is 
projected to grow as the population ages (Heidenreich, 2011; Population Resource
Center, 2011). One manifestation of poor outcomes in HF is the excessive admission- 
readmission cycle. This is particularly important to the VA healthcare system wherein 
20% of veterans with HF are readmitted within 30 days (Heidenreich, 2011). Non­
adherence to medication has been shown to be both prevalent in persons with HF, and 
responsible for the majority of hospital readmissions (Albert, 2008; Esposito, Bagchi, 
Verdier, Bencio, & Kim, 2009; Ho, Bryson, & Rumsfeld, 2009; Munger, Van Tassell, & 
LaFleur, 2007; Murray, et al., 2009). Two key factors in poor medication adherence 
include poor HL and Cl (Hawkins, 2012; Morrow, 2006). A recent pilot study was 
designed to target Cl as an underlying cause of medication non-adherence; a major 
limitation was that no information on HL was collected as part of that study. HL may 
actually have mediated the relationship between key independent variables (including the 
intervention) and the outcome measure of medication adherence. This study sought to 
answer the research question: what are the direct and indirect effects that reading HL and 
numeracy HL and other key variables (including the intervention) had upon medication 
adherence in cognitively impaired veteran outpatients with HF based on prior data from 
an interventional study testing a pictorial medication sheet and alarmed pillbox to 
improve medication adherence?
Chapter 2: Review of the Literature
This chapter includes a survey of the relevant current literature to provide a 
context for the study. The research will be situated within an existing theoretical 
framework, and a brief concept analysis will be included to clarify the main construct of 
“adherence”. The relationships between the study and previous work conducted on the 
topic will be evaluated, and the current gap in the knowledge that this study sought to 
answer will be described.
Conceptual Model
The use of a theoretical model helps describe complex systems, and ensures 
appropriate variables are studied when designing research and clinical interventions. 
Riegel and Dickson (2008) propose a conceptual model of HF self-care. This model 
described HF self-care in five stages: stage one: self-care maintenance (symptom 
monitoring and treatment adherence) and stages two through five: self-care management 
(recognition of, response to, and evaluation of symptoms). Each stage involves a series of 
naturalistic, or “real world”, decisions made by the patient. Adherence is viewed as only 
one part of the multifaceted self-care process (Riegel et al., 2009). The authors consider a 
separate construct, self-care confidence, as moderating and/or mediating all five stages in 
the model (Riegel & Dickson, 2008).
The HF self-care model was selected to serve as the theoretical framework for this 
dissertation research as it reflects the complex and iterative nature of daily decisions 
made by persons living with HF regarding their treatment plan. The presence of Cl and/or
poor HL may exert an influence on decision-making at any of the five stages in the 
model, as well as on the construct of self-care confidence. For the purpose of this study 
the influence of Cl and/or poor HL will be addressed as primarily affecting stage one: 
treatment adherence, specifically, medication adherence.
Figure 1. Conceptual Model
Figure 1. HF self-care in five stages: stage one: self-care maintenance (symptom 
monitoring and treatm ent adherence) and stages two through five: self-care 
management (recognition of, response to, and evaluation of symptoms). Each stage 
involves a series of naturalistic decisions made by the patient. Adherence is viewed as 
only one part of the multifaceted self-care process. The construct of self-care 
confidence moderates and/or mediates the self-care process. From "A Situation-specific 
Theory of Heart Failure Self-care," by B. Riegel and V. V. Dickson, 2008, Journal of 
Cardiovascular Nursing, 23, p. 192. Copyright 2008 by Lippincott, Williams & Wilkins. 
Reprinted with permission.
Adherence
Adherence is frequently used to replace an older term, “compliance”, when
Self-Care of Heart Failure Model




describing the relative success of a patient in following a plan of care. Adherence
suggests a more active, independent role on the part of the patient; compliance is thought 
to reflect a more paternalistic attitude towards a passive patient (Aronson, 2007; Gould & 
Mitty, 2010). Closely related to adherence and compliance is a newer term: 
“concordance”. Concordance reflects the ideal partnership between an empowered patient 
and enlightened provider jointly formulating a plan of care (Carpenter, 2005; Edwards, 
Davies, & Edwards, 2009). Each of these three terms, when examined closely, gives 
inference as to why the patient may not successfully follow the plan of care:
1. Non-compliant: patient choosing to not ‘obey’ the given plan.
2. Non-adherent: something interferes with the ability to adhere, although the intent 
may be there.
3. Discordant: the patient and the provider did not arrive a mutually agreeable plan.
There is much discussion in the literature regarding the usage of these closely 
related terms and they are often used interchangeably in journal articles and in clinical 
practice (Carpenter, 2005). However, adherence is the most frequently used term, and 
was term chosen by the World Health Organization (Sabate, 2003) and the U.S. National 
Institute of Health (Adherence Research Network, 2010). In addition, this dissertation 
research will examine how underlying Cl and/or poor HL influence the person’s ability to 
adhere, which most closely matches inference number two, above. Therefore, the term 
“adherence” will be used in this research proposal.
Importance of medication adherence in HF outcomes
The American healthcare system is facing unprecedented challenges in the 
demand for and the delivery of care. A key driving force behind many of these changes
is the rapidly aging population; by 2030, there will be about 72.1 million persons over 65 
years old, more than twice the number in 2000 (US Department of Health and Human 
Services, 2012). This shift in demographics brings along an attendant rise in the multiple 
and progressive chronic diseases often seen in the elderly (Population Resource Center, 
2011).
HF serves as an archetypical disease to illustrate these transformational changes 
in American healthcare. HF has been termed an epidemic due to the increasing numbers 
of cases, the intensity of care they require, and the direct and indirect costs incurred 
(Heidenreich, 2011; Lloyd-Jones et al., 2010). Admissions for HF in a recent review of 
Medicare data showed high in-hospital mortality (4.4%) and high readmission rates; 
specifically, 60% of patients had one or more readmission for any cause within the first 
nine months, and 28% were readmitted for heart failure (Aranda, Johnson, & Conti, 
2009). In the VA system, up to 20% of patients are readmitted for HF within 30 days 
(Heidenreich, 2011). This high rate of hospitalization has led to cost estimates of over 
$37 billion for heart failure care in the VA alone (Heidenreich, 2011). Many of these 
readmissions may have been prevented if patients were to engage in consistent self-care 
including adherence to medication (Cutler & Everett, 2010; Heidenreich, 2004; Riegel et 
al., 2009). Poor adherence to medication in persons with HF is common, with estimates 
ranging from 33 from 58% (Albert, 2008; Cutler & Everett, 2010; Heidenreich, 2004; 
Ho, Bryson & Rumsfeld, 2009; Wu, Moser & De Jong, 2009). Healthcare stakeholders 
recognize this; non-adherence has been termed the next frontier in quality improvement 
in cardiovascular outcomes research (Heidenreich 2004).
Medication non-adherence in persons with HF. Non-adherence to medication may be 
the most common cause of HF exacerbations and subsequent hospital readmissions in the 
United States today; and this is quoted widely in the literature. However, when sources of 
this quote are closely examined it appears that the reported outcomes, such as hospital 
readmissions, are often in reference to cardiovascular disease (e.g. hypertension, coronary 
artery disease, or myocardial infarction) rather than HF alone. (Albert, 2008; Cutler & 
Everett, 2010; Osterberg & Blaschke, 2005). However, this is not unreasonable as 
hypertension, coronary artery disease, and prior myocardial infarction are the most 
common pre-disposing etiologies of HF in America (Lindenfeld et al., 2010).
Esposito et al. (2009) examined medication adherence in persons with HF with 
healthcare usage and costs in Medicare and Medicaid data in four states. This study 
showed improved medication adherence was related to fewer hospitalizations and 
emergency room visits, and that overall treatment costs for those with 95% medication 
adherence were 15% less than those with adherence between 80 and <.95%; p  = < .01 
(Esposito, Bagchi, Verdier, Bencio, & Kim, 2009). Murray et al. (2009) studied 
pharmacy refill data in a cohort of 192 HF subjects and found medication adherence < 
40% to be associated with a three-fold higher incidence of rehospitalizaton for HF than 
those whose adherence was > 80%. Both of these studies utilized pharmacy refill data 
that may not accurately reflect patient-level adherence, and they did not establish a link to 
causes of non-adherence.
Definition of cut point for adherence. There is some disparity in defining the cut point 
for “adherent” versus “non-adherent”. Pharmaceutical trials have generally defined taking 
80% of study medication as “adherent”, although the rationale for this cutoff is not well
defined (Osterberg & Blaschke, 200S). Non-adherence is usually thought of as missing 
medication doses, however it may manifest in various ways, including underdosing, 
overdosing, self-imposed drug holidays, and taking medication that is not prescribed—all 
by the same patient (van der Wal & Jaarsma, 2008). In persons with HF, a minimum 
medication adherence of 88% has been shown to predict improved event-free survival, 
and a recent trial found all-cause mortality to be associated with <80% adherence to HF 
medications (Fitzgerald et al., 2011; Wu, Moser, & De Jong, 2009). One study of 
medication adherence and Cl in veterans with HF found poor adherence to medication 
(78%) in the overall study cohort; and that adherence significantly worsened (73%, p  =. 
017) in those subjects with mild Cl (Hawkins, 2012).
Measurement of medication adherence. Currently, there is no gold standard used to 
measure medication adherence. Methods of measuring medication adherence may be 
described as direct or indirect. Direct methods, which include directly observed therapy 
and detecting levels of the drug or its metabolite in the serum or the urine, are not 
practical for routine clinical use (Ho, Bryson & Rumsfeld, 2009; Osterberg & Blaschke, 
2005). Indirect methods include asking the patient about adherence, collecting patient 
questionnaires or diaries, assessing clinical response, performing pill counts, ascertaining 
rates of refilled prescriptions, and using electronic medication monitors (Lee, 2007; 
Osterberg & Blaschke, 2005). Recent clinical trials have used electronic devices, such as 
the Medication Event Monitoring System (MEMS), which register the date and time 
when caps of medication bottles are removed (Wu, Moser, Chung & Lennie 2008). Such 
devices have been shown to be valid instruments in measuring adherence of one or two 
medications in research settings, but are impractical to use when measuring adherence to
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the multiple medications prescribed in routine care. Pill counts are relatively easy to 
perform for any amount of medications, have been correlated in accuracy to electronic 
monitors, and have been frequently used in randomized controlled clinical trials (Lee, 
2007; Smith, Hankins, Hodson & George, 2010).
Interventions to improve adherence
Interventions have been tested to improve medication adherence in persons with 
HF that largely focused on the healthcare system and providers. In one study of 314 low- 
income patients with HF, subjects were assigned to usual care or a pharmacist-led 
intervention for nine months; with a three-month follow up. Adherence improved in the 
interventional group (78.8% vs. 67.9% in the usual care group) but this effect disappeared 
once the intervention ceased (Murray et al., 2007). A systematic review of 79 randomized 
controlled trials confirmed most interventions to improve medication adherence in 
persons with HF did not have a large or sustained effect. The interventions that did have 
an effect were complex and required involvement of multiple disciplines (Haynes, 
Ackloo, Sahota, McDonald & Yao, 2008). Thus, it is not surprising that attention has 
turned to examining patient-related factors for designing interventions to improve 
adherence.
Patient-related factors and medication adherence in HF. HF usually occurs later in 
life in persons with multiple other chronic diseases such as diabetes, coronary artery 
disease, and depression (Lindenfeld, et al., 2010). These potentially frail patients are 
confronted with potential polypharmacy and a fragmented medical care system that does 
not offer reimbursement incentives to the healthcare provider for careful medication 
reconciliation (Cutler & Everett, 2010).
Moser and Watkins (2008) point out the normative model in American healthcare 
is the delivery of care on an acute, episodic basis. However, HF is a chronic disease, and 
daily attention, or adherence, to multiple factors such as taking medications is needed to 
maintain stability. The patient in the home must manage this ongoing process of self- 
care. Self-care occurs as a result of a series of decisions made by patients, and thus 
interventions to improve self-care may fail if little is known about the factors affecting 
decision-making. The presence of Cl and/or poor HL may influence decision-making, 
but this has not been well studied in veterans with HF.
Cognitive Impairment in HF
For the purposes of this study Cl may be defined as ranging from mild to severe 
(dementia), manifesting as problems with memory, attention, learning, recall, motor 
speed, reaction times, and executive functioning (Sauve, et al. 2009). Cl has been shown 
to be a frequent condition in patients with HF, far above what is to be expected with 
normal aging. A population-based study of 1075 persons in Italy found the risk of Cl 
was 1.96-fold greater in those with HF (Cacciatore et al. 1998). A literature review of 22 
studies from 1966 to 2006 compared pooled data from 2937 HF patients with 14,848 
controls and concluded the odds ratio of HF patients having Cl to be 1.62 (Vogels, 
Scheltens, Schroeder-Tanka & Weinstein, 2007). Another literature review of Cl in HF 
found the prevalence of Cl ranged from 30-80% (Bennett & Sauve, 2003). A third review 
of the literature from 2002-2007 examined 97 longitudinal studies and found the 
prevalence of Cl in HF to be 25% to 50% (Pressler, 2008). This wide variance in 
prevalence is probably due to the small select samples of very ill hospitalized patients
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included in the reviews. Thus these results may not be readily generalized to the 
outpatient HF population. In addition, instruments used to measure Cl varied widely.
More recently, cognition has been studied in outpatients with HF using 
sophisticated neuropsychogical instruments. One study tested of 414 participants (249 
HF, 63 healthy, and 102 medical participants, i.e. those with conditions other than HF); 
those with HF were found to have 24% more cognitive deficits than the controls. The 
domains affected were primarily memory, psychomotor speed and executive functioning 
(Pressler, Subramanian & Kareken, 2010). Another study compared 50 outpatients with 
HF compared to age-matched controls in the community. All subjects completed 
neuropsychological testing, and those with HF were found to have a four-fold risk for Cl 
compared to controls (Sauve et al., 2009). None of these studies have evaluated the 
association of poor HL or medication adherence in persons with HF and Cl.
Causal factors for Cl in HF. It is unknown if the increased occurrence of Cl with HF is 
due to a direct causal association, or if both conditions are associated with certain patient 
demographics such as advanced age and co-morbid disease states including diabetes, 
anemia, sleep apnea, or stroke (U.S. National Library of Medicine, 2012). Previous 
studies have suggested that low cardiac output, as well as variations in blood pressure are 
associated with Cl, particularly in patients with ischemic cardiomyopathy (Kennelly, 
Lawlor & Kenny, 2009; Woo, Kumar, Macey, Fonarow & Harper, 2009). Depression is 
prevalent in persons with HF and is associated with both Cl and with poorer overall 
outcomes (Hawkins et al. 2012, Rutledge, Reis, Linke & Greenberg, 2006). Prior 
literature has also focused on the association of Cl with biomarkers for disease severity, 
including increased B-type natriuretic peptide (BNP), serum creatinine, and glycated
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hemoglobin, as well as derangements in thyroid function, serum vitamin B12, and 
thiamine levels (Lindenfeld et al., 2010).
Health Literacy
As important as Cl may be in contributing to poor medication adherence and thus, 
poor outcomes, it is only one of many factors. A related, yet separate concept is poor 
health literacy (HL), which may be described as an individual’s capacity to obtain and 
process basic health information and negotiate the healthcare system well enough to 
obtain necessary services and make appropriate health decisions (Nielsen-Bohlman, 
Panzer, & Kindig, 2004). Health literacy is not simply a problem of reading fluency and 
vocabulary (and thus is not dependent upon educational level), but instead is affected by 
multiple factors such as the complexity of the information presented, and the patient’s 
contextual knowledge, prior experience, and cognitive and functional abilities 
(Evangelista, et al. 2010; Nielsen-Bohlman, Panzer, & Kindig, 2004; Moser and Watkins
2008). Numeracy skills, a subset of HL, are less discussed in the literature, yet are critical 
to managing such common tasks as taking medication. For example, Davis et al. (2006) 
found 70 % of patients with poor HL could correctly state the instructions on a 
medication label, yet only 34% could actually demonstrate the number of pills to be 
taken.
HL is usually categorized in three to five ordinal levels e.g. “below basic” (no 
more than simple, concrete literacy skills), “basic” (simple and everyday literacy skills), 
“intermediate” (moderately challenging literacy skills) and “proficient” (complex and 
challenging literacy skills). Multiple articles cite the extremely high incidence of poor HL 
in America; and usually reference the seminal National Assessment of Adult Literacy
(NAAL) study, which published data in 2003 showing only 13% of Americans possess 
HL at the proficient level (National Center for Educational Statistics, 2012). 
Disproportionately high levels of poor HL were found in vulnerable populations 
including racial and ethnic minorities, the frail elderly, and those with low incomes 
lacking health insurance.
Health literacy, Cl and outcomes. Healthcare providers remain largely oblivious of the 
fact that the majority of their patients may have difficulty reading and understanding 
healthcare information, and continue to provide their patients with written prescription 
labels, consent forms, test preparation instructions, test results, health questionnaires, and 
the like. Patients with low literacy are likely to feel anxious and ashamed about 
communicating with the provider, and also may not tell anyone that they do not 
understand basic health concepts (Parikh, Parker, Nurss, Baker & Williams, 1996). Poor 
HL has been associated with poor outcomes such as non-adherence to treatment plans, 
poor self-care behaviors, poorer physical and mental health, increased risk of 
hospitalization, and increased mortality (Wolf, Gazmararian, & Baker, 2005). The effect 
of HL on medication adherence in patients with cardiovascular disease in a large health 
maintenance organization revealed patients with inadequate HL were at increased risk for 
poor adherence (odds ratio: 1.37; 95% Cl 1.08 to 1.74) compared to those with adequate 
HL. However, this rinding did not achieve statistical significance once adjustments were 
made for age, race, gender, education and regimen complexity, suggesting another factor 
may influence adherence (Keller, Wright & Pace, 2008). A study of 492 community 
dwelling adults with hypertension found that Cl greatly reduced the influence of age, 
education and race on HL scores (Levinthal, Morrow, Tu, Wu, & Murray, 2008).
However, this study enrolled primarily African-American females, and thus may not be 
generalizable to the VA population of primarily Caucasian males. There is only one 
interventional study evaluating improving medication adherence in HF by addressing HL; 
314 low-income patients were randomized to usual care versus an intervention that 
included face-to-face support with a pharmacist and materials designed for patients with 
low health literacy. The interventional arm did show increased adherence, however, this 
decreased back to baseline once the intervention ceased (Murray, et al. 2007). In 
addition, only five medications were used in this study, which does not reflect the 
polypharmacy often found in clinical practice (Hawkins et al., 2012).
Health literacy and veterans with HF. In America, low health literacy is a prevalent 
and clinically under-recognized problem that directly impacts patient’s self care skills, 
including medication management, and up to 57% of patients with HF may have poor HL 
(Evangelista et al., 2010; Moser & Watkins, 2008; Morrow, 2006). One study conducted 
in four VA medical facilities assessed HL in 1,786 veterans. This study showed veterans 
actually had a lower prevalence of poor HL than what has been reported in the civilian 
population; specifically only 8.3% had inadequate and 11.8% had marginal skills (Griffin 
et al., 2010). There are no studies reporting the prevalence of poor HL in the veteran 
population with HF.
Cl and HL in persons with HF. Memory and verbal fluency are decreased in patients 
with Cl (Hawkins et al. 2012; Pressler, Subramanian & Kareken, 2010; & Sauve et al.
2009). Yet, both are needed to negotiate a HF patient’s complex medication regimen that 
often requires thoughtful action based on evaluation of daily vital signs. Memory and 
verbal fluency have also been found to be associated with poor HL, after controlling for
18
mild Cl (Federman, Sano, Wolf, Siu & Halm 2009). Thus, interventions to improve 
adherence in patients with low HL should also reduce demands on cognitive abilities. The 
commonly accepted view that utilizing simple language and a series of illustrations for 
health information will not help low-literacy patients if the pictures must be mentally 
integrated to be understood (Morrow, et al. 2006).
Summary
HF is an epidemic threatening to overwhelm American healthcare. Poor 
medication adherence leads to poor outcomes as evidenced by the excessive admission- 
readmission cycle for HF. This is particularly important to the VA, the largest managed 
healthcare system in the U.S. It is becoming increasingly clear that traditional models of 
patient education to improve adherence are failing. Novel interventions, targeted to 
improve adherence, and therefore, outcomes, by addressing underlying problems with Cl 
and poor HL are needed. This literature review demonstrates the paucity of research in 
veterans with HF about the effect of Cl and HL on medication adherence. A gap exists in 
the current knowledge, as nothing has been documented about the prevalence of poor HL 
in veterans with HF, or the relationship between Cl and HL on interventions designed to 
improve medication adherence in this population.
Significance of Dissertation Research to Advancement of Nursing Knowledge
Unfortunately, there remains a lack of awareness on the part of healthcare 
providers regarding the negative effects of poor HL and Cl on adherence and outcomes in 
their patients with HF. There is also a paucity of data on how to address these problems 
in actual clinical practice. Most interventions attempting to increase adherence have
focused on the healthcare system or the provider. In addition interventions have been 
tested in populations stratified by illness, e. g. HF, coronary disease or hypertension, 
rather than the unaddressed but underlying patient-related factors such as Cl and poor 
HL. Knowledge about the mediating effect of HL on an intervention targeted to improve 
MA in veterans with HF and Cl will help inform the design and implementation of future 





The specific aims of the study were to:
Aim 1. Describe level of HL in the study population.
Aim 2. Determine the strength and direction of the relationships between reading HL and 
numeracy HL and selected clinical and demographic variables in the study population.
Aim 3. Determine the direct and indirect effects that reading HL and numeracy HL and 
other key variables (including the intervention) had upon medication adherence in 
cognitively impaired veteran outpatients with HF based on prior data from an 
interventional study testing a pictorial medication sheet and alarmed pillbox to improve 
medication adherence.
Research Design
The study was a retrospective, correlational, cross-sectional design using 
secondary analysis of data from the completed TARGET pilot study. Selected clinical 
and demographic variables, and reading HL and numeracy HL scores were retrieved from 
the participant’s medical records. The TARGET study did not include information on 
HL, yet reading HL and numeracy HL scores were available from the participant’s 
medical records. Thus this design was selected to estimate the causal relationships 
between reading HL and numeracy HL (included in existing outpatient medical records), 
the intervention, other key variables, and medication adherence in a sample of cognitively
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impaired outpatient veterans with HF who participated in an interventional pilot study 
testing a pictorial medication sheet and alarmed pill box to improve medication 
adherence.
Participant characteristics
Setting. All study procedures were conducted at a large metropolitan Veteran’s 
Administration facility, which serves an urban population of 246,000 veterans in southern 
California.
Inclusion and exclusion criteria. All subjects in the pilot study were 18 years old or 
older, had an established clinical diagnosis of HF, and screened positive for Cl using the 
Saint Louis University Mental Status (SLUMS) exam (Tariq, Tumosa, Chibnall, Perry & 
Morley, 2006). In order to participate in testing the pictorial medication sheet and 
alarmed pillbox, participants were required to speak and read English, follow simple 
directions, be able to see, and have the manual dexterity to take their own medications. 
Thus persons with severe functional limitations, acutely decompensated HF, dementia 
requiring a caregiver, or severe mental illness, such as active schizophrenia, were 
excluded. Subjects were also excluded if they had a life expectancy of less than 6 months.
Sampling Procedures
Sampling method. The sample included subjects (n=40) from the TARGET pilot study. 
These subjects were recruited as a convenience sample from the investigator’s outpatient 
HF clinic.
Sample size and power analysis. The TARGET study was designed as a pilot study to
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test feasibility and effectiveness of the intervention. Thus, no power analysis was 
conducted.
Data Collection Procedures
Data was retrospectively collected from the TARGET database and the electronic 
medical record, and entered into an Excel spreadsheet on the investigator’s secure, 
password-protected computer. Subject ID numbers were assigned sequentially, and all 
data was de-identified. A master subject/linkage log was retained in a separate locked 
research file in the investigator’s office. Any pen-and-paper files related to the study, as 
well as IRB documents, were maintained in a separate, locked research file in the 
investigator’s office.
Human Subjects Considerations
Prior to any data collection or analysis permission to conduct the study was 
obtained from both the VA Loma Linda Healthcare System’s IRB and the University of 
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N/A Continuous, ordinal, 
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1 Short Test of Functional Health Literacy for Adults
2 Ejection fraction
3 to reflect disease severity: serum creatinine, hemoglobin, B-type natriuretic peptide, and 
glycated hemoglobin; to reflect those usually associated with cognitive impairment: 
thyroid stimulating hormone and vitamin B-12
4 Systolic blood pressure
5 New York Heart Association functional class for HF severity
The data on the dependent variable, medication adherence, was obtained for each 
subject from the 30-day pill counts collected before and after the prior TARGET study 
intervention. To capture both overtaking and undertaking medication, a change score was 
determined for each prescribed medication by computing the absolute difference between 
the number of pills taken versus the prescribed number over the 30-day period. The 
change score values for each medication were summed for each individual subject, 
divided by the total number of pills prescribed, subtracted from 1, and finally multiplied 
by 100 to obtain an adherence score expressed as a percentage. Thus, a value of 100% 
indicated all pills were taken correctly. A value of 85% meant that 15% of prescribed 
pills were either not taken, or overtaken, or a combination of both. All currently 
prescribed medications were included in the pill counts except medications taken on an 
“as needed” (pm) basis, injectables, and inhaled medications. Over the counter 
medications were not included.
Data related to health literacy was based on participant’s scores on the Short Test 
of Functional Health Literacy for Adults (S-TOFHLA). This instrument was derived from 
the longer Test of Functional Health Literacy for Adults (TOFHLA) that was designed to 
assess basic reading and numerical tasks encountered by patients in a healthcare setting 
(Parker, Baker, & Williams, 1995). The S-TOFHLA has been shown to be valid, 
reliable, and easily administered in a busy clinical setting (Bass, Wilson, & Griffith, 
2003). It is a timed (seven minute) reading comprehension test using the modified Cloze 
procedure; the patient reads common medical instructions that have every 5th to 7th word 
in a passage omitted and is asked to select a word from 4 multiple-choice options to fill in 
the blank spaces (Bass, Wilson, & Griffith, 2003; Parker, Baker, & Williams, 1995). This
test has been administered to patients in the HF clinic as part of usual care since January 
2011. In addition, there is a 17-item, timed (ten minute) subscale of the TOFHLA that 
tests the ability of patients to comprehend medication prescription labels, results of blood 
glucose tests, clinic appointment slips, and financial assistance for healthcare 
information. The numeracy subscale is scored in a weighted manner according to the test 
manual, to create a final score ranging from 0-50 (Parker, Baker, & Williams, 1995). The 
numeracy subscale had been administered to all T ARGET participants as part of routine 
HF clinical care. All HL scores are recorded on HF clinic progress notes, which are 
maintained in the electronic medical record. There is no evidence in the literature that 
HL scores as assessed by S-TOFHLA change over time.
Statistical Analysis
Study data was entered into an Excel database, then transferred into the computer 
program, Statistical Package for the Social Sciences v. 20 (SPSS) (IBM Corporation), for 
analysis. A p-value of .05 or less was considered significant. Initially, frequency 
distributions for each variable were examined for normal distribution characteristics. 
Then descriptive and inferential statistical analysis were performed as appropriate.
Descriptive statistics including measures of central tendency and frequency were 
employed to address study aim 1: Describe the level of reading HL and numeracy HL in 
the study population. Study aim 2, that addressed the strength and direction of the 
relationships between reading HL and numeracy HL and selected clinical and 
demographic variables in the study population, was explored using bivariate correlational 
tests appropriate to the level of measurement (e.g. Spearman’s rho for ordinal data and
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Pearson’s r for interval or ratio level data). To achieve aim 3: Determine the direct and 
indirect effects that HL and other key variables (including the intervention) had upon 
medication adherence in cognitively impaired veteran outpatients with HF based on prior 
data from an interventional study testing a pictorial medication sheet and alarmed pillbox 
to improve medication adherence, structural equation modeling (SEM) was utilized for 
analysis. This analysis was performed using Mplus v.7 software (A/plus, 2012), in 
consultation with a statistician experienced in SEM.
SEM was selected as the best method to estimate the causal relationships between 
HL, the intervention, other key variables and medication adherence. SEM offers an ideal 
method of analysis as models can be constructed to reduce measurement error and 
accommodate the complexity of the factors and relationships being studied. In addition, 
though not a panacea for problematic distributions or model misspecification, the 
bootstrapping option in Afplus was considered to address the small sample size in the 
study population (Meyers, Gamst & Guarino, 2006).
Strengths and Limitations of Methods
There are important limitations to this research design. The sample size was 
small, drawn from a pilot feasibility study, and was selected as a convenience sample 
from the investigator’s HF population of predominantly elderly Caucasian males veterans 
from an urban southern California VA medical center. The VA system offers ready 
access to prescription medication coverage. Therefore, the results may not be readily 
generalized to other populations. There is the recognized difficulty in objectively 
measuring actual medication adherence with the pill counting technique. There is no data
available to know if HL scores obtained from the S-TOFHLA instrument would change 
over time.
Strengths of the design actually mirror some of the limitations. The study sample 
is homogeneous, and all have ready access to prescription medication coverage.
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A B S T R A C T
Oajzcnvzs: The study objectives were (a) to describe the prevalence and severity 
of cognitive impairment (Cl) in an outpatient veteran population with heart 
failure (HF), (b) to describe the cognitive domains affected in those subjects 
found to have Cl, (c) to examine clinical and demographic variables that may be 
associated with Cl, and (d) to determine the relationship between Cl and 
medication adherence (MA). We hypothesized that Cl is a prevalent condition in 
veterans with HF and is associated with poorer MA. Adherence to therapy is 
essential for successful outcomes. Cl may affect adherence; little is known about 
Cl in veterans with HF or the effect of Cl on MA.
Mith o ds: We enrolled 251 veteran outpatients with HF. Subjects were screened 
for Cl; adherence was determined by pill counts. Subjects with Cl underwent 
further neuropsychologic testing.
Risu l t s : Unrecognized Cl was found in 58% of subjects. Verbal learning, 
immediate memory, and delayed verbal memory were most impaired. Cl was 
significantly associated with poorer MA. Variables associated with Cl included 
age, African-American race, depression, use of alcohol, and nonparticipation in 
pill count.
Conclusion; Unrecognized Cl was prevalent and associated with poorer MA. We 
propose routine screening for Cl in patients with HF.
Ciw this article Hiwkiru, L. A., Kilian. S., Firek, A, Kaihner, T. 14., Fink, C . a Silvet, H. (2012, ■/■). 
Cognitive impairment and medication adherence in outpatients with heart failure. Heart R Lung, ■ (■), 1-
11. httpy/dx.doi.org'10,1016/j.hrtlng.2012.06.001.
Heart failure (HF) is a  prevalent, complex, and chronic 
medical condition th a t currently affects 5.8 million 
people in  th e  United States, contributing significantly to 
increased m ortality, morbidity, and healthcare expen­
ditures, and decreased quality o f life.1*2 The negative 
im pact o f HF on  patient outcomes and healthcare costs is
projected to escalate as th e  American population ages 
and is o f particular im portance to the  Veterans Affairs 
(VA) health  care system , the  largest integrated health ­
care system  in the  United S ta te s .14 Outpatient encoun­
ters for HF in th e  VA system  have increased from 550,000 
in  2002 to  900,000 in 2009 and represent not only the
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increasing num bers of veterans w ith HF but also the 
increasing intensity of care these patients require.4
Large clinical trials have dem onstrated the  success 
o f pharmacologic and lifestyle strategies in improving 
patien t outcom es and have resulted in the  develop­
m en t o f consensus guidelines.1 However, patients w ith 
HF tend  to  be older and to  have m ultiple comorbidities, 
and m ay find it difficult to follow these often complex 
regim ens, thereby losing the  benefits o f evidence- 
based care.4’s One particularly im portant m anifesta­
tion o f poor HF outcom es is the  frequency of 
adm issions. In the  VA system , 20% of patients w ith HF 
are readm itted  w ith in  30 days.4 Nonadherence to 
m edication has been  show n to be responsible for the  
m ajority o f readm issions for HF in th e  United States.5" 
10 Of even m ore concern, a  recent trial linked medica­
tion nonadherence, defined as < 80% adherence to HF 
m edications, to all-cause m ortality.11 Thus, identifica­
tion and intervention for key factors contributing to 
poor m edication adherence (MA) have become primary 
goals for clinicians and healthcare policymakers.4
Pharm aceutical trials have generally defined taking 
80% of study m edication as “adherent,'' although the 
rationale for this cutoff is no t well defined.12 In persons 
w ith HF, a  m inim um  MA of 88% has been show n to 
predict im proved event-free survival.13 Population- 
based studies have show n MA to be as low as 40% to 
50%, highlighting the  im portance of focusing on 
adherence to  improve pa tien t outcom es.5,12"15
Adherence is a complex issue and depends on multiple 
patient and healthcare-related factors. Nonadherence is 
usually thought o f as m issing medication doses; 
however, it m ay m anifest in various ways, including 
underdosing, overdosing, taking self-imposed drug holi­
days, and taking m edication that is no t prescribed—all by 
the sam e patient.16 The World Health Organization's 
Multidimensional Adherence Model classifies predictors 
of poor adherence into 5 broad domains: socioeconomic 
status, type of healthcare system, prescribed therapy, 
condition being treated, and individual patient-related 
factors.17 However, this model explained less than  20% 
of poor adherence in patients with HF, emphasizing the 
need to identify o ther contributors to nonadherence in 
this population.11 One frequently overlooked factor that 
m ay influence all of these domains is the presence of 
cognitive im pairm ent (Cl).
Cl m ay range from mild to severe (dementia), m an­
ifesting as problem s w ith memory, attention, learning, 
recall, m otor speed, reaction tim es, and higher level 
orders of reasoning (executive function).19 It is clini­
cally intuitive th a t  im pairm ent in  any of these dom ains 
w ould negatively affect patients ' abilities to correctly 
take th e ir m edications, yet assessm ent for Cl rem ains 
rare in clinical practice.20"22 Persons with HF have been 
show n in recent studies to have up to  a  4-fold higher 
risk o f developing Cl com pared w ith the  general pop­
ulation, and th e  overall prevalence of Cl in outpatients 
w ith HF has been show n to be as high as 50%.19,23 A 
lim itation of previous studies exam ining Cl in HF is the 
selective inclusion of persons w ith  low left ventricular
ejection fraction (LVEF), despite the  fact th a t > 50% of 
HF adm issions in th e  United States are for patients 
w ith preserved systolic function.1 In addition, these 
studies have no t exam ined the  direct relationship of Cl 
to  MA in a selected population.
It is unknow n w hether the increased occurrence of 
Cl w ith HF is due to  a  direct causal association or if both 
conditions are associated w ith certain patient dem o­
graphics, such as advanced age and comorbid disease 
states, including diabetes, anem ia, sleep apnea, and 
stroke.19,23 Previous studies suggest th a t low cardiac 
output and variations in blood pressure are associated 
w ith Cl, particularly in  patien ts w ith ischem ic cardio­
m yopathy.19,24,25 Depression is prevalent in persons 
w ith HF and associated w ith both Cl and poorer overall 
outcom es.15,26 Prior literature h a s  also focused on the 
association of Cl w ith biom arkers for disease severity, 
including increased B-type natriuretic peptide, serum  
creatinine, and glycated hemoglobin, as well as 
derangem ents in  thyroid function, serum  vitam in Bu , 
and thiam ine levels.27"29
The older American veteran is a t risk for m any of 
these comorbid illnesses. For example, the  m ajority of 
veterans w ith HF have ischem ic heart disease and 
approxim ately one third have diabetes.4 In addition, the 
effects o f post-traum atic stress disorder and substance 
abuse in th e  veteran population on HF outcom es are not 
well understood. To date, there  are no published studies 
on  the  prevalence of Cl and  its  potential effect on  MA and 
outcom es in  the  outpatient veteran population with HF.
There are several advantages to conducting this 
investigation in  a  veteran  population. The VA system  
presents a large and  relatively controlled environm ent 
o f m anaged care, and data collection is facilitated by 
a well-established, com prehensive electronic medical 
record system . In addition, veterans have increased 
access to  care com pared w ith th e  general population, 
including assistance w ith transportation to  clinic 
appointm ents. Most im portant, m edications are 
provided from th e  VA form ulary a t no cost or for a  low 
fixed co-pay. Yet despite th is seemingly ideal system, 
HF outcom es rem ain  problem atic as evidenced by the 
excessively high readm ission rate.4
The objectives o f th is study w ere (a) to describe the 
prevalence and severity o f Cl in an  outpatient veteran 
population w ith HF, (b) to describe the  cognitive 
dom ains affected in those subjects found to  have Cl, (c) 
to exam ine clinical and  demographic variables that 
may be associated w ith Cl, and (d) to determ ine the 
relationship betw een Cl and MA. We hypothesized th a t 
Cl is a  prevalent condition in  veterans w ith HF th a t is 
associated w ith poorer MA.
M aterials a n d  Methods
This study w as designed as a prospective observational 
cohort study a t a  large m etropolitan Veterans
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A dm inistration facility, which serves an urban 
population o f 246,000 veterans in southern California. 
The institutional review board approved the  study, and 
all subjects provided w ritten inform ed consent before 
enrollm ent.
Study Population
Clinical providers and research coordinators screened 
all eligible patien ts for th e  study w ho presented to  the  
ou tpatien t HF and general m edical clinics a t a  VA 
m edical cen ter betw een December 2009 and March
2011. Patients w ere eligible for enrollm ent if  they had 
an established clinical diagnosis of HF. Recruitment 
w as no t based on  specific lim its of LVEF. Persons with 
a life expectancy of less th an  6 m onths o r docum ented 
dem entia requiring a caregiver were excluded from the 
study. To participate in cognitive function testing, 
participants w ere required to speak English, follow 
sim ple directions, and  be able to draw  sim ple figures. 
Thus, patien ts w ith severe functional lim itations, 
acutely decom pensated HF, o r severe m ental illness, 
such as schizophrenia, were not included. No subjects 
had  know n Cl before enrollm ent into the study.
Procedures
At th e  initial study visit, all subjects were screened for 
Cl, depression, and propensity to adhere to their 
prescribed m edication regimen. Selected clinical and 
dem ographic variables w ere collected by direct patient 
interview  using standard  questions and  medical record 
review. Subjects w ere asked to return  for a second and 
th ird  study visit bringing in their regularly prescribed 
m edications for a  d irect 30-day pill count to determ ine 
MA. Subjects w ho initially screened positive for Cl were 
invited back for a  fourth study visit to undergo a neu ­
ropsychologic te s t battery. Screening, interviewing, 
and  data  collection w ere conducted by 2 research 
coordinators under the  supervision of the  investiga­
tors. The study flowsheet is presented in Figure 1.
Variables and Measures
Screening fo r Cl
Subjects w ere screened for Cl using the  Saint Louis 
University M ental Status (SLUMS) exam ination.30 The 
SLUMS exam ination consists of a  30-point education 
adjusted, clinician-adm inistered interview scale that 
classifies patien t im pairm ent as none, mild, or 
im pairm ent consistent with dem entia. Specifically, 
SLUMS screening is considered positive for mild Cl if 
the  score is < 27 in a  person w ith a  high school diploma 
or < 2S in  a  person w ho did no t complete high school. 
SLUMS screening is considered positive for severe 
im pairm ent consistent w ith dem entia if  th e  score is 
< 21 for persons w ith a high school diploma and < 20 
for persons w ho did no t com plete high school.
The SLUMS exam ination contains 11 questions th a t 
incorporate tasks correlating w ith specific cognitive
Cl Screen potlttve
Subjects who meet inclusion criteria ate enrolled
Modified neuropsychological 
battery
All subjects bring in medications for pill count
1. Subjects screened for cognitive impairment with SLUMS exam 
2. Clinical/demographic variable collection
All subjects return for 30-day repeat pill count to determine 
adherence
Figure 1 -  Study flo w sh e e t (3, confidence interval; 
SLUMS, Sain t Louis U niversity M ental Status.
dom ains. These include im m ediate recall and orien­
tation  (day of week, year, and place); delayed recall 
w ith interference (subjects are asked to rem em ber 5 
objects and recall them  after 2 intervening questions); 
num eric calculation and registration (a 2-part m ath  
story problem); sem antic  fluency (naming as m any 
anim als as possible w ithin 1 minute); working m em ory 
(reciting num bers backward), visual spatial and exec­
utive function (dock-drawing test); visual spatial 
function (recognizing geometric figures); and contex­
tual verbal m em ory (subject listens to a sho rt story and 
answ ers 4 questions about th e  story 's content).
The SLUMS exam ination w as selected for our study 
for several reasons. The SLUMS exam ination contains 
empirically derived cutoff scores based on a  study of 
702 patients from  an urban VA system  w ith dem o­
graphics sim ilar to our sam ple of predom inantly 
elderly Caucasian m en.33 This validation study indi­
cated th a t th e  SLUMS exam ination had  high sensitivity 
(98%-100%) and specifirity (98%-100%) for detecting the 
p resence of dem entia. In addition, th e  SLUMS exam i­
nation w as show n to be m ore sensitive in detecting 
m ild Cl th an  th e  fam iliar Mini Mental Status Exam, 
w ith  sensitivity o f 93% versus 67% for patients w ith less 
than  high school education, and 94% versus 67% for 
patien ts w ith a high school diplom a or above.33*33 The 
SLUMS exam ination includes a  dock-draw ing test, 
w hich is especially sensitive in detecting impaired 
executive function.34 Finally, th e  SLUMS exam ination 
is quick to adm inister, taking approxim ately 7 m inutes, 
and m ay be conveniently downloaded a t no charge 
from the  Internet.35
Neuropsychologic Testing
Our study w as designed to further test those subjects who 
screened positive for Cl to determ ine the cognitive
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dom ains m ost affected. To be tolerable for older subjects 
with HF, a modified comprehensive battery of neuro­
psychologic testing was chosen that could be completed 
in one 2-hour session. In addition to brevity o f adminis­
tration, tests were selected on the basis of (a) sensitivity to 
the  presence o f Cl including dementia, (b) available test 
norm s with demographic adjustments, and (c) published 
research establishing good psychometric properties of 
each in stru m en t The domains tested included imm e­
diate and delayed verbal memory, delayed nonverbal 
memory, visuospatial/constructional ability, language, 
verbal learning, attention, information processing speed, 
executive functioning, m otor dexterity, and premorbid 
intellectual functioning. The specific tests included 
Repeatable Battery of Assessment of Neuropsychological 
Status,36 Trail Making Tests,37 W echsler Test o f Adult 
Reading,36 Grooved Pegboard Test,39-40 phonemic and 
sem antic verbal fluency tasks,41,43 and Similarities, 
Matrix Reasoning, Letter Number Sequencing and Digit 
Span subtests from  the W echsler Adult Intelligence Scale, 
4th edition.37,43 All examinations were conducted and 
scored by a  single research coordinator trained in 
psychometric testing under the supervision of our 
neuropsychologist investigator.
Screening for Depression
The Geriatric Depression Scale (GDS) screens for 
depression in  th e  elderly.44 It is a widely used self- 
report consisting of 30 sim ple yes/no questions su it­
able for th e  ill or th e  m ildly cognitively impaired 
person. The GDS has an  acceptable reported internal 
consistency of .94 (Cronbach's alpha) and a  split half 
reliability o f .94.44,43 Cutoff scores are as follows: 0 to  9 
as norm al, 10 to 19 as m ildly depressed, and 20 to 30 as 
severely depressed.
Demographic and Clinical Variables
Demographic and clinical variables th a t m ight predict 
or influence th e  finding of Cl in the  study sam ple were 
selected on  the  basis o f review of relevant literature as 
described in  th e  introduction. These data  were orga­
nized into 5 categories: demographic, health-related, 
HF-related, behavioral health-related, and clinic- 
related variables. Demographic data  included age, 
gender, ethnicity, living arrangem ents, employment, 
educational level, and self-perceived financial distress. 
Health-related variables included systolic blood p res­
sure, the  presence of selected comorbidities (diabetes, 
hypertension, obstructive sleep apnea, stroke, and 
atrial fibrillation) and  selected laboratory values 
(B-type natriuretic  peptide, glycated hemoglobin, 
serum  creatinine, thiam ine, vitam in B12, hemoglobin, 
and thyroid stim ulating horm one levels). Venipunc­
ture and blood specim en processing were conducted as 
p a rt o f routine m edical care a t the  VA’s clinical labo­
ratory. HF-related variables included HF cause, HF 
duration, and LVEF as m easured by echocardiogram. 
Behavioral health-related  variables included docu­
m ented  history  of depression, depression as m easured
by GDS, docum ented history o f post-traum atic stress 
disorder, and self-reported use  o f tobacco, alcohol, 
m arijuana, o r illicit substances. Clinic-related variables 
included trea tm en t provided by the  specialized HF 
clinic versus general medical clinics, num ber of 
prescribing providers, and num ber of hospitalizations 
in the  past year. The num ber and type of prescribed 
m edications w ere collected during the  pill counts on 
those subjects who retu rned  for pill counts.
Screening for Propensity to Adhere to 
Medication
All subjects w ere screened for propensity to adhere 
using d ie  Medication Adherence Estimator.46 This 3- 
item  instrum en t w as designed to estim ate a patient’s 
propensity to adhere to m edications prescribed for 
chronic disease and w as validated in  a large sam ple of 
elderly patients using pharm acy claims data  over a  9- 
m onth  period.47 Respondents are scored as low, 
m edium , o r high risk for nonadherence.
Medication Adherence
Subjects were asked to  bring their regularly taken 
prescription m edications to be counted a t the  beginning 
o f the  study and again a t 1 m onth  to obtain a  direct 30- 
day pill count. T he pill count included all prescribed 
m edications, no t only those for HF, to  reflect overall pill- 
taking behavior. Medications taken on an  as-needed 
basis, injectables such as insulin, and inhaled medica­
tions were excluded from  th e  pill co u n t Two research 
coordinators counted pills in th e  clinic in the  presence of 
th e  subjects, both m anually and  w ith a  Toibal DRX 300 
NTEP (Fulcrum Inc., Clifton, NJ) certified pharm acy scale.
An MA score for each subject was computed from 
the  30-day pill counts. To capture both overtaking and 
undertaking m edication, a ‘‘delta’ w as determ ined for 
each m edication by com puting the  absolute difference 
betw een the  num ber o f pills taken and the  num ber 
prescribed over the  30-day period. The delta values for 
each m edication w ere sum m ed for each individual 
subject, divided by th e  total num ber of pills prescribed, 
subtracted from 1, and finally multiplied by 100 to 
obtain an adherence score expressed as a percentage. 
Thus, a  value o f 100% indicated th a t all pills were taken 
correctly. A value o f 85% m ean t th a t 15% of prescribed 
pills were no t taken, overtaken, or a combination of 
both. Expressed m athem atically, if the  j th  patient w as 
prescribed pjt and consum ed cjt o f m edication i, then  
MA can be com puted for each jth  p a tie n t
S ta tis t ic a l A n a ly s is
Data analysis w as conducted using the  Statistical 
Package for th e  Social Sciences version 19 (SPSS Inc,
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Chicago, IL).48 P values of .05 or less w ere deem ed 
significant. Descriptive sum m aries included m eans 
and standard  deviations for continuous variables and 
counts and  percentages for categorical variables. To 
facilitate m aking sem antically interpretable com pari­
sons o f relative effect sizes across variables, neuro­
psychologic test scores, age, and LVEF variables were 
transform ed into z scores by subtracting the  sam ple 
m ean  from  th e  raw  score and dividing th e  difference by 
th e  sam ple standard  deviation.
To achieve study objective “a," SLUMS scores were 
obtained for each subject. The SLUMS scores calculate 
Cl as a 3-item  ordinal scale (none, mild, and im pair­
m ent consistent w ith dementia). For the  initial anal­
ysis, subjects w ere identified as “no Cl* or “CL” For 
fu rther analysis, subjects w ith Cl w ere further grouped 
in to  2 categories', m ild ot  severe (im pairm ent consis­
ten t w ith dementia).
To achieve study objective "b,” neuropsychologic 
test scores w ere standardized on the  basis of the indi­
vidual te s t m anual or published demographically 
adjusted test norm s.49
To achieve study objective “c,” unadjusted associa­
tions am ong clinical, demographic, and Cl variables 
w ere assessed  using Spearm an's rho for ordinal vari­
ables o r Pearson’s tests for interval or ratio variables. 
Predictors o f Cl w ere com puted from univariate 
generalized linear regressions w ith an  ordinal m ulti­
nom ial link and robust standard  errors. For categorical 
predictors (eg, race), effect sizes on  Cl w ere reported as 
sim ple odds ratios. For continuous predictors (eg, age), 
effect sizes on Cl were reported as odds ratios repre­
sen ting  th e  change in  th e  likelihood of increasing Cl by 
1 level (eg, none to m ild im pairm ent, or mild to  severe 
im pairm ent) for a  change in 1 standard  deviation of the 
predictor variable.
To achieve study objective “d,“ unadjusted and 
adjusted associations betw een Cl and MA were 
estim ated  using generalized linear regression. Esti­
m ates were adjusted for age, race (African-American), 
ethnicity (Hispanic), living arrangem ents (living alone), 
num ber o f hospitalizations in the prior year, and 
tobacco use. These adjustm ent variables w ere selected 
to  contain demographic and health-related factors 
identified by a literature review and the  predictor's 
perform ance on  this dataset to explain MA or Cl.
Results
A total o f 251 subjects were recruited. The ethnically 
m ixed population served by the  hospital (predomi­
nantly  60% Caucasian, 9% African-American, and 8% 
Hispanic) w as fairly well reflected in the  study sam ple 
o f 72% Caucasian, 13.6% African-American, and 9.6% 
Hispanic subjects. Subjects were predom inantly m ale 
(99%), w ith a  m ean age o f 66 years (standard deviation 
±  9.8; range, 33-93 years). Baseline characteristics for 
th e  cohort are show n in Table 1.
W e found a high prevalence of unrecognized Cl in 
our cohort; 58% (144/2S0) o f patients had  Cl based on 
the  SLUMS screening test; 41.6% of these had mild Cl 
and 16% had  severe im pairm ent consistent w ith 
dem entia (Table 2). All subjects w ho screened positive 
for Cl during th e  initial study visit w ere invited back for 
fu rther neuropsychologic testing. Despite vigorous 
efforts by th e  study team , only 61% (89/144) actually 
retu rned  for fu rther testing. Of th e  cognitive dom ains 
tested, verbal learning, im m ediate mem ory, and 
delayed verbal m em ory were found to  be the  m ost 
im paired based on a  z score o f < -1 .5 . Results of neu- 
ropsychologic tes ts  are show n in  Table 3.
Table 4 presents the  results o f bivariate analyses 
betw een study variables and CL G  w as positively 
associated w ith age, African-American race, depres­
sion as m easured by th e  GDS, and use of alcohol, in  
addition, Cl w as associated with not returning for pill 
counts; however, th is is no t a  variable th a t could easily 
be identified in a clinical setting.
Although all study subjects (both those w ith and 
w ithout Cl) initially agreed to re tu rn  for the  pill count, 
only 67% (168/250) o f th e  enrolled subjects did so. 
Overall adherence in th e  cohort o f patients who 
participated in  th e  pill count w as poor; subjects w ith  no 
Cl h ad  adherence o f 78%, those w ith m ild Cl had 
adherence o f 70%, and  those with severe Cl had 
adherence of 73%. Specifically, compared with no Cl, 
MA significantly w orsened by  8 percentage points (78% 
to  70%, P = .017) for patien ts w ith mild Cl, bu t did no t 
continue to  w orsen for patients with severe Cl in the  
dem entia range. Similar findings were found betw een 
unadjusted  and adjusted estim ates (Table 5).
Our regression analyses revealed a  robust associa­
tion betw een th e  presence of Cl and MA. Among the  
study variables listed in  Table 4, only Cl w as found to 
have a  statistically  significant association w ith MA. W e 
also found both overtaking and undertaking prescribed 
m edications to  be com m on in our study sample; 
however, no statistically significant patterns or trends 
w ere found.
Results from the  Adherence Estimator survey 
revealed the  m ajority o f subjects intended to take 
their m edications. Specifically, 52.2% (116/214) scored 
a t low risk, 35% (75/214) scored a t m edium  risk, and 
10% (23/214) scored a t high risk for potential non­
adherence. However, these scores were no t signifi­
cantly correlated w ith actual MA found in the  study 
population.
D iscu ssio n
Our study dem onstrated  2 im portant findings: a  high 
prevalence of previously unrecognized Cl in  veterans 
w ith HF and  the  association o f Cl w ith poorer MA. 
These findings have vital implications for the 
successful trea tm en t of HF in the  veteran population.
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Demographic verifies History of depression (h + 298) 76(303%)
Age (y) mean ± SD 66,4 *9.8 GDS score, mean *  SD* 13,3*3.80
Male gender (n -  251) 247(98.4%) PTSD (n -  251) 47(18.7%)
Race/ethnidty (n -  250) Tobacco use (n -  248)
Caucasian 180 (72.0%) Never smoked 47 (19.0%)
African-American 34(13.6%) Former smoker 154(62.1%)
Hispanic 24(9.6%) Currant smoker 47(19.0%,
Employment (n -  248) Alcohol use (n-251)




Retired Current use 5  3 drinks/wk
Unemployed 11 (4.4%) Currant use >3 drinks/wk 29(11.6%)
Living arrangements (n -  249) Marijuana use (n + 248)
Live alone 68(27.3%) Never 156(62.9%)
Live with spouse/partner 142 (57.0%) Pasture 78(31.5%)
Live with children 17 (6.8%) Current use 14(5.6%)
Other 22 (8.8%) Other illicit substance use
Education (n «  248) (n -2 4 8 )
Less than high school 25 (10.1%) Never 190(76.6%)
High school diploma 60 (24.2%) . Pasture 57(23.0%)
SomecoQsgp 103(41.5%) Cunentuse H*%)
College degree or above 60(24.2%) Clinic-related variables :
Self-perceived financial status Treated in specialised HF clinic 143 (57.0%)
(n -  221) (n-251)
Doe* not affect ability to care 111(50.2%) NO. of prescribing providers, 5.4*2.4(1-13)
for health mean *  SD (range)
Affects ability to care for 110 (49.8%) No. of hospitalizations in past .58*112(0-7)
health year, mean *  SD (range)
Health-related variables HF medications (n - 168)
Diabetes (n -  251) 134(53.4%) ACE inhibitor 128(76%)
Coronary artery disease 160(63.7%) Angiotensin receptor Mocker 52(31%)
192(114%)(n -  251) Beta-blocker
Hypertension (n + 251) 193(76.9%) Diuretic 176(105%)*
Obstructive shiepapnea 68(27.1%) Digordn 47 (W%) 
31(19%)(n -  251) Isosoibide/hydralazine
History of stroke (n -  251) 26(10.4%) Aldosterone antagonist 38(23%)
History of atrial fibrillation 82(32.7%) No. of prescriptions (n -168), 7.83 *  3.06 (1-17)
(n-251) mean *  SD (range)
Systolic blood pressure mean * 
SD (mm Hg)
Thiamine level, mean *  SD 
(nmol/L)
Vitamin Bna level, mean *  SD 
(pg'mL)
Hemoglobin level, mean *  SD
WW
Serum creatinine level, mean * 
SD (m^dL) 
Thyroid-stimulating hormone, 
mean * SD (uIU/mL)
BNP * SD (range) (pg/mL) 
HgbAic ± SD (range) (%) 
HF-related variables 










LVEF, mean * SD
125.8 *  19.67














37.5 *  16.90
_ \CE, angiotensin-converting enzyme, BNP. »-typs nStri- 
_ rretic peptide; GDS, Geriatric Depression Scale; HF, heartL 
_ failure; HgbAic, glycated  hemoglobin; LVEP, left ventricular, 
_ Section fraction; PTSD, post-traumatic stress disorder; SD,
_ itandard deviation.
- 'Diagnosis based on d u e t review.
.  jScore O-9 -  normal,10-19 -  mild depression, 20-30 -
- revere depression.
-I  May reflect  combination  diuretic therapy.-------------------
o f  ( < >cj n !  i v i  ■ j  n  111
' 111 v> -i ■ . ! \  h o i .
' M i ,
Hone f
Mild impabrment 
Severe impairment (dementia) 
SLUMS score, mean *  SD (range) 
SLUMS administra tion time in 
minutes, mean *  SD (range)
t i t  (414X1 
104(41.6%) 
40(16.0%) 
24.39 *  4,0 (12-30) 
7.1*1.4(4-15)
(continued)
- 3, cognitive impairment; SLUMS, Saint Louis Univerrit) 
-Mental Status; SD, standard, deviation .11 ■ ■ — —
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*4  in
7
T . ib h *  I R e s u l t s  o l  i n - i n  o p s y c  i i o l o ^ i c  t e s t i n i ; '
Estimate of premoiMd IQ WTAR 69 9.867(81-119) 98.71
Attention WAIS-IV digit span 84 .88 (-167  to 10) -.60
WAIS-IV tetter-number sequencing 
age<69y
54 .68 (-3.00 to 133) -.56
Information processing speed Trails A 89 .99 (-3.80 to 1.40) - X
RBANS coding 89 .87 (-3.81 to 4.3) -1.196
Language RBANS picture naming 89 1.34 (-9.33 to .90) 1257
Animate 88 1.17 (-3,20 to 2.10) -.57
RBANS semantic fluency 89 £8 (-2.85 to 1.74) -.8645
Visuospatial abilities RBANS figure copy 89 1.53 (-6.00 to 1.35) -.6670
RBANS line orientation 89 .85 (-2,28 to 1.29) .1030
WAIS-IV matrix reasoning 84 .98 (-133 to 2.00) -.20
Verbal learning RBANS list teaming 89 .96 (-4.92 to .96) -1.904*
RBANS story memory 89 1.08 (-3.92 to 1.0) -1.589*
Delayed verbal memory RBANS list recall 89 .91 (-186 to .95) -1145
RBANS flat recall recognition 89 1.84 (-7.67 to .67) -1,798*
RBANS story recall 89 1.21 (-4.14 to .91) -1840*
Delayed nonverbal memory RBANS recall figure 89 1.04 (-3.4 to 1.97) -.3637
Executive functioning COWAT 88 .90 (-3.0 to 1.30) -.74
Trails B 88 1.04 ( - IS  to 10) -.73
WAIS-IV similarities 84 .70 (-2.0 to 1.33) -.17
Motor dexterity Grooved pegboard Dominant hand 85 1.08 (-3.60 to 1.40) -.70
Grooved pegboard nondominant hand 83 1.12 (-3.5 to 1.80) -.91
.  30WAT, Controlled Oral Word Auociadon Test; IQ, inteffigence quotient; R8ANS, Repeatable Battery of Assessment of Neu- _ 
_ropsychologicel status; SD, standard deviation; WAIS-IV, wechsler Adult Inteliigenoe Scale, 4th edltiwvWlWVSf'eehslarTosi.  
. i f  AdultReedlng.
<-1.5 SD considered impaired. ■■
.  1 AD standardixed scorn  are presented in x scores with the exception of estimate of premorttid IQ (Wechsler Test of Adull_ 
J t eadintf, whieh la presented In a standard score with a mean of 100 and 6D of  15.------------------ *— ----- .-------  L
Previously unrecognized Cl w as found in 58% of our 
sam ple o f veterans w ith HF. This prevalence, although 
unexpectedly high, is consistent w ith o ther studies 
conducted in nonveteran outpatients w ith HF.19 23 in 
our veteran  population, we found the  expected positive 
association of Cl w ith age. Other significant associa­
tions included African-American race, use of alcohol, 
depression as m easured by the  GDS, and increased 
likelihood of no t returning for the  pill count. Comor­
bidities show n in prior literature to be associated with 
Cl in HF, including abnorm alities in blood pressure, low 
LVEF, o r ischem ic cause of HF, were not found to be 
statistically significant in our study sample. This 
discrepancy m ay be explained by the  heterogeneous 
population in  our study th a t included outpatients w ith 
all-cause HF com pared w ith prior studies th a t m ay 
have preferentially evaluated sicker patients.
The cognitively im paired subjects who completed 
further neuropsychologic testing  dem onstrated 
significant deficits in th e  dom ains o f verbal learning, 
im m ediate m em ory, and delayed verbal m emory. This 
effectively m eans th a t m any cognitively impaired 
patien ts will no t understand, or will forget, w hat the  
provider h a s  ju s t  instructed  th em  to do soon after 
leaving th e  clinic environm ent. By extension, in ter­
ventions th a t rely on traditional models o f patient 
education to  im prove adherence would likely fail in 
th is pa tien t group. The m ajority of subjects w ho failed
to re tu rn  for testing  sim ply did no t re turn  multiple 
telephone m essages or respond to w ritten rem inders to 
do so. It is unknow n w hether this reflects another 
aspect o f poor adherence associated w ith Cl or w hether 
o ther factors, such as no t w anting to spend th e  tim e or 
no t clearly understanding w hat was expected o f them , 
contributed to  the  low rate o f return. This intriguing 
discovery deserves additional investigation in future 
studies because of th e  potential im pact on actual 
adherence estim ates.
C onsistent w ith our original hypothesis, Cl was the 
only factor studied th a t w as found to be associated 
w ith poorer MA in our study population. The im pact on 
adherence seem ed to begin with mild Cl and did no t 
continue to  w orsen for patients w ith severe Cl in  the 
dem entia range. This is particularly im portant to clin­
ical practice because th e  presence of m ild Cl is easily 
missed; th e  patient, who m ay deny needing any 
assistance w ith m edication adm inistration, often 
hides m em ory loss.*-10 We are uncertain as to why the  
m ore severely affected subjects did no t have worsened 
MA. It is possible these  subjects were actually receiving 
assistance from  family m em bers or others; however, 
living arrangem ents (alone or w ith others) w ere no t 
significantly associated w ith MA in our study sample. 
Finally, i t  is unknow n w hether subjects were non­
adheren t before becom ing cognitively im paired or 
w hether prior nonadherence actually contributed to Cl.
OR 95% Cl Chi-square
( ? )




Age (z score) 1.41 1.03-1.92 4.66(1) .031 1.42 1.03-1.95 4.64(1) .031
African-American race 3.22 1.70-6.09 12.95 (1) <.001 3.59 1.90-6.81 15.4(1) <.001
Hispanic race 2.17 1X12-4.60 4.09(1) .043 2.27 .971-5.30 3.58(1) .058
Uves alone f i l l .492-1.34 .679(1) .410 .817 .489-1.36 400(1) 439
Health-related variables
Diabetes .960 .598-1.54 .029(1) .865 .931 .561-1.54 076(1) .782
Thiamine (z score) 1.10 .942-159 1.48(1) .224 .982 .803-1.20 032(1) 458
TSH (z score) 1.21 .865-1.68 1.22 (1) MA<09 1.06 .741-1.51 497(1) .756
Vitamin B« (z score) 1.19 .950-1.48 2.28 (1) .132 1.16 .903-1.48 132(1) .250
Hemoglobin (z score) .735 -590-.917 7.48(1) .006 .789 .608-1.02 3,19(1) .074
Creatinine (z score) 1.35 1.01-1.81 3.98 (1) .046 1.27 .960-1.68 2.80(1) .094
HF-related variables
Duration of HF
1-5 y 154 .583-4.04 .753(1) .385 1.50 .549-4.12 .630(1) ,427
6-10 y 1.02 .380-.271 .001(1) .977 .833 .303-229 .126(1) .723
>10 y .970 .343-2.74 •003(1) .954 .987 .327-2.97 401(1) .981
Cause of HF
ischemic v* nonischemic .894 .553-1.45 .208(1) .648 1.11 650-149 181(1) .707
LVEF(z score) 1.16 .936-1.44 1.85(1) .174 1.12 .893-1.41 .987(1) .321
Systolic BP (z score) 1.22 3.79-7.44 354(1) .072 1.14 .903-144 1,23(1) .268
Behavioral health-related variables
Geriatric Depression Scale 1.38 1.09-1.74 7.11(1) .008 1.43 1.12-143 8.08(1) .004
fz score)
Tobacco use
Never or prior .546 .295-1.01 3.72 (1) .054 .591 .312-1.12 2.63(1) .105
Current smoker .436 •209-.910 .489 (1) .027 •S45 .259-1.15 2-56(1) .109
Alcohol use
Never 134 .736-2.43 .911(1) .340 1.47 .791-2.72 1-48(1) .224
Former use 1.67 .868-850 2.36(1) 124 2.13 106-4.31 44? (1) .034
. Current use 3 drinks/wk 396 ■48-191 *79(1) .052 236 .055-100 m m .050
Currentuse 4*7 drinksfwh 1.62 .379-6.93 .425(1) .514 lfi2 .384-8.62 468(1) .451
Current use >B drinks/wk 1.62 .481-5.46 .608(1) .436 1.93 .505-7.39 •924(1) .336
Marijuana use
Never or prior .608 .368-1.01 3.77(1) .052 .913 .526-1.58 .106(1) .745
Current use 1.10 .607-1.98 .095(1) .758 1.75 .820-3.71 2,09(1) .148
Clinic-related variables
HF clinic patient .639 .395-1.04 3.31 (1) .069 .745 .443-1.25 1-23(1) .267
Did not return for pill count 2.33 1.41-3.88 10.7 (1) .001 2.03 1.20-3.45 645(1) 409
Hospitalized in past year 1.08 .935-1.25 1.10(1) .294 1.14 .960-1.35 2.21(1) .137
.  3P, blood pressure; a ,  confidence interval; HF, heart failure; LVEF, left ventricular ejection fraction; OR, odds ratio; 
.rSH.thyroid-stiinulating hormone.
-'Based On SLUMS screening.
_ 1 Adjusted for age, African-American race, Hispanic ethnicity, living alone, tobacco use, and number of prior hospitalisation* .
J n  past year.-------------------------    — •------ ------------------ ■— ■--------- :---------------— :------- •—-------—------ [_
Implications for Practice
Overall MA w as poor in our cohort, w ith subjects both 
overtaking and undertaking their medication. Over­
taking m edication h as no t received m uch attention  in 
th e  literature bu t poses potentially serious patient 
safety issues. In a m ultim orbid population, this 
problem  is com pounded by polypharm acy prescribed 
by m ultiple providers. In our study, it w as not 
uncom m on to find patients with several bottles o f the 
sam e m edication and taking a tablet from each one. 
W e found patien ts m ost often knew their m edications 
by color and  shape  ra th e r than  by nam e or indication.
This is particularly im portan t in th e  VA system  
because generic m edications are m ailed to patients' 
hom es from a centralized pharmacy. Changes in 
vendors used by th e  pharm acy frequently resulted in 
changes in  tablet appearance; patients m ay no t 
recognize th a t th e  new  tablet is actually the  sam e 
m edication. Potentially harm ful m edication errors can 
be discovered by careful m edication reconciliation 
during clinic visits. However, accurate m edication 
reconciliation requires tim e and expertise and is 
neither routinely recognized as an  im portant part of 
care nor reim bursed in  th e  curren t m odel of healthcare 
delivery.1114
k s s m s  s f e
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C o g n i t i v e  i m p . i i i  n i tM i t  ,u u I  m r d i c . i t i o n  a d l i n e n r c  (n
Adherence 95% Cl Chi-square
m
P value Adherence 95% <8 Chi-square
m
P valu
None 81.1% 77.1-85.0 m Ref 78.1% 70.5-852 Ref R tf
Mild 74.1% 6M-7&5 5.22(1) .022 70.7% 63.0-78.4 528(1) .017
Dementia 74.0% 65.9-82.1 2.33(1) .127 732% 63.3-83.4 103(1) .310
- 3, confidence Interval
'Adjusted for age, African-American race, Hispanic ethnicity, living done, tobacco use, and number of admissions to thi
A large proportion of our study participants indi­
cated on the  Adherence Estimator questionnaire th a t 
they  in tended to  adhere to their m edication regimen, 
yet overall their actual MA was poor, and clearly the 
presence of Cl contributed to w orsening adherence. 
Unfortunately, curren t clinical practice guidelines do 
no t recognize Cl as a  risk factor for poor adherence. 
Consideration should be given to screening all patients 
w ith HF for Cl using  a tool such as the  SLUMS exam i­
nation, w hich can be adm inistered in less th an  10 
m inutes by regular clinic staff.
In addition, th e  m ean score on the  GDS (13.3, stan ­
dard deviation ±  3.80, n  =  249) indicated th a t the  
average participant in the  study w as mildly depressed. 
However, the  prevalence of previously diagnosed 
depression in  th e  study sam ple based on medical 
record review w as only 30.3% (n =  250). These findings 
confirm  th e  comorbidity o f depression in persons w ith 
HF and suggest it m ay be another easily m issed diag­
nosis in th is population. Depression is known to affect 
inform ation processing and has been show n to be 
prevalent and associated w ith worsened outcom es in 
nonveterans w ith HF.15-26 Therefore, screening for both 
Cl and depression m ay be o f particular im portance in 
veterans w ith HF.
Implications for Further Research
HF is a  chronic disease th a t disproportionately affects 
the  elderly and  presents w ith o ther conditions, such as 
diabetes or hypertension. Successful outcom es depend 
on adhering to trea tm en t regim ens th a t are often highly 
complex and require significant cognitive ability to 
comply. Our findings suggest th a t Cl m ay be a  key factor 
in clinical success or failure, and indeed a  large portion 
o f th e  ou tpatient population w ith HF m ay be affected by 
th e  im pact o f  unrecognized Cl on MA. Further research 
is needed to  develop and tes t interventions to improve 
MA by specifically targeting underlying Cl. Consider­
a tion should be given to interventions th a t specifically 
address potential problem s w ith verbal learning, verbal 
m em ory, and  delayed verbal memory.
Study Limitation*
Our study had several im portant lim itations. It was 
conducted in a predom inantly m ale veteran
population in an  urban com m unity in  southern  Cal­
ifornia, w here patien ts have ready access to m edica­
tions via prescription m edication coverage; the  results 
of our s tudy  m ay therefore no t be readily generalized 
to  o ther populations. There is th e  recognized difficulty 
in  objectively m easuring actual MA with the  pill 
counting technique. We had a  higher nonreturn  rate 
for cognitively im paired patients for the  pill count. 
However, we predict th a t these patients would have 
had  a t least as poor, if  no t worse, adherence com pared 
w ith th e  o th er subjects with Cl who did follow up; 
thus, our da ta  m ay overestim ate actual MA. There was 
also a h igh nonreturn  rate  for cognitively impaired 
subjects to  re tu rn  for fu rther neuropsychologic testing. 
Although th e  SLUMS exam ination has been validated 
in  a veteran population as a  sensitive screening tool, 
any brief screening is no t considered adequate to 
m ake quantitative conclusions about Cl. In addition, 
the  association of Cl w ith African-American race, 
although significant, w as based on a sm all segm ent of 
the  overall study population and therefore should be 
interpreted w ith caution. Finally, we did no t include 
health  literacy as part o f th e  study design; impaired 
health  literacy m ay further affect patien ts’ abilities to 
understand  and c an y  out self-care and m edication 
regimens.
Conclusio ns
On th e  basis o f our clinical experience and previous 
studies, w e hypothesized th a t veterans w ith HF would 
have a  high prevalence of Cl and th a t the  presence of Cl 
would negatively affect MA. Our study found th a t 
unrecognized Cl w as highly prevalent and associated 
w ith poorer adherence to m edication in our sam ple of 
older ou tpatient veterans w ith HF. Verbal learning, 
im m ediate m em ory, and delayed verbal m em ory were 
th e  cognitive dom ains m ost affected. Our findings 
suggest th a t Cl m ay be a key factor in  clinical success or 
failure in  th is challenging population. Consideration 
should be given to screening all veterans w ith HF for Cl 
to identify those w ho will need additional help  with 
adherence. Further research developing interventions 
to improve MA by targeting underlying problem s w ith 
Cl is urgently needed.
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A. Background
A.1 ■ Heart failure is a  significant burden in the VA health care system.
Heart failure [HF] is a  prevalent, costly, chronic, and complex condition that impacts an 
increasingly larger number of people as  the population ages. In the VA system, 
hospitalizations and encounters for HF are on the rise, reflecting the growing number of 
veterans who are impacted by this chronic condition that drastically impacts quality of life 
[QOL], morbidity and mortality, and greatly increases expenditures for VA health care. In 
2009, over 96,000 hospitalizations in the VA system listed HF a s  a  diagnosis, a  30% 
increase from 2002.1 The CHF QUERI2009 Strategic Plan lists reducing hospitalization 
rates, increasing use of care known to prolong survival and improve QOL, and 
empowering the patient for self-management as  their top goals.1 
A.2. HF outcomes are related to adherence.
Evidence-based medication and lifestyle strategies have shown to decrease mortality 
and hospitalizations for HF and improve QOL, and are included in the current published 
guidelines that summarize recommended clinical regimens.2,3 However, the successful 
implementation of these published guidelines in clinical practice remains challenging.2'4 
HF patients tend to be older, with multiple comorbidities, and can find it difficult to follow 
complex management regimens, resulting in poor adherence and the loss of the proven 
benefits of guideline-based care. In fact, not adhering to medication regimens has been 
shown to be the most common cause of HF exacerbations and subsequent hospital 
readmissions; a  recent trial linked poor adherence (defined a s  <80% adherence to HF 
medications) to all cause mortality.5'14 
A.3. Adherence  is multifactorial.
Adherence depends on complex patient and healthcare factors.5,8,5,10 Specifically, 
medication adherence [MA] refers to both compliance (the extent to which behavior 
coincides with health advice; e.g. patients take their medication a s  prescribed, such a s  
twice daily), and persistence (following treatment recommendations over time).0,17 The 
World Health Organization’s  Multidimensional Adherence Model classifies predictors of 
poor adherence into five domains: socio-economic, health care system, therapy, 
condition, and patient-related domains.18 However, the factors outlined in this model 
explain less than 20% of poor adherence in HF patients, highlighting the need to identify 
other important drivers of non-adherence in this population.19,23 One relatively 
overlooked factor that may influence all of these domains is the presence of cognitive 
impairment [Cl].
A.4. Cl has been associated with adherence in non-HF populations in prior studies.
Prior studies in the elderly have shown that even mild cognitive dysfunction interferes 
with the patient’s  ability to adhere to self-care and medication regimens, yet assessm ent 
for Cl remains rare in clinical practice.21'23 Cl manifests a s  problems with memory, 
attention, learning, motor speed, reaction times and executive functioning (i.e., higher- 
order capacities such a s  cognitive flexibility, concept formation, initiation, inhibition, 
selective attention, planning, and problem-solving).24 It is clinically intuitive that Cl would 
directly lead to poor MA based on the tasks commonly confronting HF patients such as  
learning what pill to take, remembering to take it, and having the dexterity and 
sequencing skills to open pill bottles and count tablets. Unfortunately, while the cognitive 
processes needed to manage and take medications often decline with aging, the number 
of prescription and nonprescription medications consumed is likely to increase. Although 
the relationship between patient’s  cognition and MA appears intuitive, prior studies 
evaluating the prevalence of Cl in HF have not evaluated the link between Cl and patient 
outcomes, including MA.
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A.5. Cl is common in patients with HF.
Previous studies evaluating Cl in HF patients have documented a  high rate of Cl, 
ranging from 30-50%.25'32 Most of these prior studies were limited to small sam ples of 
hospitalized patients, such as  those awaiting heart transplant, and thus not applicable to 
the patients seen in everyday clinical practice. However, two recent outpatient studies 
also demonstrated increased incidence of Cl in patients with HF compared to matched 
community controls, consistent with the results found in patients with end-stage HF.24,33 
No studies have evaluated Cl in the outpatient veterans with HF, or the association to 
MA. Our recently completed CHF QUERI funded pilot study Cognitive Impairment as a 
Risk for the Admission-Readmission Cycle seen in Veterans with Heart Failure: Closing 
the Adherence Gap 34, examined both the prevalence of Cl in outpatient veterans with 
HF and the association of Cl with MA.
A.6. Our CHF QUERI funded study provides the basis for an intervention study to 
improve MA.
Our study recruited 251 outpatients with HF at VA Loma Linda Healthcare System 
[VALLHCS]; data collected included screening scores for Cl, 9-item demographic 
survey, 17-item health survey, 10-item chart review, 7 lab results, 25 neuropsychology 
tests, a  9-item medication management survey, and a  3-item medication adherence 
attitude survey. All subjects were asked to bring in all regularly prescribed medications 
for a  direct 30-day pill count. Subjects were predominantly male (99%), with a  mean age 
of 66 years. Sixty-six percent of subjects had left ventricular ejection fraction of <40% , 
with the mean of 37.5% (SD ±16.90, range 10-85). Average number of total 
prescriptions per subject was 7.83 (SD + 3.06, range 1-17).
We found a  strikingly high prevalence of undiagnosed Cl in our cohort: 58% (144/250) of 
patients had Cl based on the Saint Louis University Mental Status [SLUMS] screening 
test; 41.6% scored in the mild Cl range and 16% in the dementia range. Of the cognitive 
domains tested, verbal learning, immediate memory, and delayed verbal memory were 
found to be the most impaired.
Although all study subjects (both with and without Cl) initially agreed to return for the pill 
count, only 67% (168/250) of the enrolled subjects did so. Returning for pill count was in 
itself associated with Cl (OR 2.03,95%  Cl 1.20-3.45, x2 =6.85, p=0.009). In the sample 
participating in the pill count, we found a  robust and significant association between the 
presence of Cl and MA. MA (calculated to reflect both overtaking and under-taking 
regularly prescribed medications) significantly worsened with mild Cl, but interestingly 
did not continue to worsen as  Cl increased in severity to the dementia range. Overall, 
adherence in the entire cohort was poor: subjects with no Cl had MA of 81%, those with 
mild Cl had MA of 74% (95% Cl 69.6-78.5, x2 5.22, p=0.022), and those with severe Cl 
(dementia) had MA of 74% (95% Cl 65.9-82.1, x2 2.33, p=0.127). These results suggest 
three clinically important findings: Cl is highly prevalent, mild Cl is sufficient to impair 
MA, and overtaking medications has an important role in nonadherence.
A.7. Different m easurements have been used to estimate medication adherence.
MA, a s  estimated in clinical trials, overestimates the true adherence in the environment 
of usual clinical practice; population-based studies have shown actual adherence to 
medications to be as  low as  40-50%.4,36,38 Medication non-adherence may take multiple 
forms, including underdosing, overdosing, self-imposed drug holidays and taking 
medication that is not prescribed—all in the sam e patient. Currently, there is no gold 
standard used to m easure MA though multiple methods are available, and include 
patient adherence questionnaires/diaries, assessing direct or indirect clinical response, 
performing pill counts, ascertaining rates of refilled prescriptions, and using electronic 
medication monitors.37'42 Pill counts are relatively easy to perform, have been correlated
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with electronic monitors, and have been frequently used in randomized, controlled 
clinical trials.4340 Recent clinical trials have used electronic devices, such a s  the 
Medication Event Monitoring System, which register the date and time when caps of 
medication bottles are removed.14,44,51'63 Such devices have been shown to be valid 
instruments in measuring adherence in research settinas, but are impractical to use 
when measuring adherence with multiple medications.14,20,54 
A.8. Prior studies  designed to improve adherence due to patient-dependent factors have 
not had a  sustained effect in patients with HF.
Multiple interventions have been tested to improve MA; however, a  systematic review by 
Haynes et al. found that most interventions studied in patients with HF did not have a  
large or sustained effect, and the ones that had any effect at all were complex and 
involved multiple disciplines.16 Intervention trials in patients with HF have used 
counselingby apharm acist, home nursing interventions, and extensive education 
p r o g r a m s . 1 Many of these interventions have shown improved MA, but the effect 
typically disappeared once the intervention was over.
A.9. Targeted interventions are more likely to be efficient and cost effective,
The existing studies have approached interventions to improve MA based on 
stratification on existing primary diagnosis (for example, HF, coronary disease or 
hypertension) rather than targeting specific determinants of non-adherence such as  Cl.
In fact, many of the interventions tested in HF populations in prior studies were patient- 
action driven and therefore likely to fail in patients who have Cl. The high prevalence of 
Cl demonstrated in our recent study suggests that this may be an important contributing 
factor in MA in patients with HF. Unfortunately, there are few if any studies providing 
guidance on how to effectively improve MA in this vulnerable population. Traditional 
interventional strategies are not effective, or do not have a  sustained effect, suggesting 
that new innovative methods are needed to improve outcomes.
We propose that interventions designed to improve MA by addressing underlying 
problems posed by Cl are likely to be more effective and less costly as  specific 
populations would be targeted to receive the appropriate level of intervention. An ideal 
intervention to improve MA in patients with Cl would be technology-driven, easy to 
implement, sustainable in the long-term, and cost-effective. It would also be targeted at 
the specific cognitive domains affected in patients with HF such as  learning and 
memory.
Based on Wu criteria for optimal adherence (the cutoff of adherence predicting event- 
free survival in outpatients with HF was 88%),14 our findings suggest that the 74% 
adherence found in our patients with mild Cl offers a  rich target for intervention to 
improve outcomes to directly meet the CHF QUERI goals of reducing hospitalization 
rates, increasing use of care known to prolong survival and QOL, and empowering the 
patient for self-management.
B. Automated Medication Dispensing Device TAMDPl.
One novel and promising technology is based on the use of the AMDD.8 ,8 This device 
is designed to improve MA and target several cognitive domains of memory, attention 
(reminding the patient to take medications on time), fine motor skills, sequencing, 
processing speed (selecting and manipulating medication bottles) and executive 
functioning (helping patients to decide which pills they should take). This device is able 
to hold up to 60 doses of medications in pre-filled cups, to be programmed a s  needed 
based on the frequency of dosing. It is equipped with an alarm mechanism that alerts the 
patient to take the medications; when the patient pushes the button on the device, it will 
dispense the medications. If medications are not dispensed at the appropriate interval 
(within 90 minutes of the pre-set time), the patient and the study staff will receive an
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automated phone call from a centralized monitoring center. The monitoring center will 
continue to ring the telephone until a  dedicated button is pushed on the phone, indicating 
the call was received. The study staff will attempt to telephone the subject to remind 
them to take their medication; and to problem-solve a s  needed.
The AMDD will be set up in the subject’s  home, and training will be provided to the 
subject and family by study staff. The medication dispenser will be pre-filled with the 
subject’s  prescribed cardiac medications by a  home health nurse once a  month (home 
health nurse will be hired on a  contract basis from the agency currently providing home 
care to patients at VALLHCS).
This device was selected for several reasons: 1) it targets the cognitive domains of 
memory, attention, sequencing, fine motor skills, processing speed, and executive 
functioning; 2) the locking mechanism promotes medication safety and prevents patient 
’’overtaking” their medications (which was found to be a  significant problem in our current 
study); 3) it provides means whereby patients with Cl may be empowered to remain 
independently in their home; 4) the centralized monitoring system will add another 
aspect to the collectable adherence data (when and how many times the phone calls 
were prompted by missed doses); 5) it is programmable to prompt patients to take 
medications with food, to check their blood glucose level, use their inhaler, etc.; 6) it has 
an eariy-dispense feature to allow for planned doses if the subject is away from home; 7) 
it is in alignment with the VA’s  philosophy of utilizing commercially available, off-the-shelf 
technology; 8) it has the potential for future device modification to allow expanded use, 
such as  collecting physical parameters (blood glucose, weight, blood pressure) and to tie 
in with the VA's commitment to health informatics, disease management, and care 
coordination/home telehealth so the veteran maintains independence.68
Q-SPWtffc Aim?.
AIM 1. Feasibility.
Our purpose is to assess  the feasibility of using the AMPP in veterans with HF and Cl. 
We powered the study to detect the “success rate” of the AMDD, defined as  both patient 
acceptance and a  clinical response to the AMDD. Clinical response is defined a s  a  9% 
increase in patient-ievel adherence and, alternatively, a  7% increase in medication-level 
adherence. The 9% and 7% represent, respectively, the adjusted mean differences in 
patient-level and medication-level adherence rates between patients with no Cl and mild 
Cl in our finished study.
Our specific aims will therefore be the following:
Aim 1A. Measure the percentage of patients with diagnosed HF who qualify for the 
AMDD based on our study inclusion/exclusion criteria (qualifying rate).
Aim 1B. Measure the percentage of qualified patients who agree to participate (consent 
rate).
Aim 1C. Measure the percentage of enrolled and consenting patients able to place the 
AMDD in their homes and use it appropriately (user rate).
Aim 1D (11. Measure the percentage of patients using the AMDD who have a  positive 
clinical response to the AMDD over a  one-month period (patient-level response rate). 
Aim ID (2). Measure the likelihood that the patient using the AMDD responds to the 
AMDD for a  given medication over a one-month period (medication-level response rate). 
Aim 1E. Measure the percentage of patients who both accept and respond to the AMDD 
(success rate).
AIM 2. Medication Adherence (exploratory analytical aim).
We will calculate the improvement of MA in patients with HF and Cl who use the AMDD, 
based on a  30-day pill count following the introduction of the AMDD.
AIM 3. Medication Adherence (qualitative aim).
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Aim 3A. Describe the reasons why enrolled patients were not able to use the AMDD.
Aim 3B. Describe patient satisfaction with the AMDD.
Aim 3C. Quantitatively describe the time spent to set up and fill the AMDD.
AIM 4, Clinical outcomes (exploratory aim).
Clinical outcomes, including readmissions for HF, are going to be important in any larger 
interventional study; we therefore included measurements of these outcomes in our pilot 
study for exploratory reasons.
Aim 4A. Measure changes in physical parameters, such as  blood pressure, heart rate, 
and weight.
Aim 4B. Measure changes in clinical/functional outcomes, such a s  New York Heart 
Association (NYHA) functional class, serum B-type natriuretic peptide (BNP) levels, and 
diuretic usage.
Aim 4C. Measure changes in utilization (emergency department visits and 
hospitalizations).
The conceptual basis for our study is explained by the model presented below. This 
model shows Cl a s  one of the factors associated with adherence, with adherence 
predicting clinical outcomes for HF such a s  readmissions, QOL, morbidity and mortality. 
We propose that an intervention with the AMDD in patients with Cl and HF will target 
adherence directly, and also indirectly by having a  moderating effect on the link between 
Cl and adherence. This pilot study will measure a  total effect and will not distinguish 
between moderating and direct effect.
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D. Research Design and Methods.
D.1. Study Design.
This study is designed as  a  feasibility study testing an intervention, with the subjects 
serving as  their own controls. Figure 2 outlines the flowsheet describing the study 
design.
D.2. Study Setting.
The study will be conducted at the VALLHCS, Loma Linda, CA, which serves a  
population of 246,000 veterans. This is an urban setting with an ethnically mixed 
population.
Figure 2. Study flowsheet.
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30-day pill count for adherence
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Screening patients for the study
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D-3, Study 
Population,
This study will enroll 
patients with HF and 
Cl from outpatient HF 
clinic. If inclusion and 
exclusion criteria are 
satisfied, patients will 
be invited to 
participate, informed 
consent will be 
obtained, and patients 
will be enrolled. 
Inclusion/Exclusion 
Criteria;
1. Outpatients with a  
diagnosis of HF 
supported by 
established criteria.
2. Cl as  measured by 
SLUMS and defined 
a s  a  score of <27 in a  
person with high 
school education of 
<25 in a  person with 
less than high school 
education.
3. English-speaking.
4. Age 18 or older.
5. Able to provide consent.
6. Able to provide a  stable home environment for at least 90 days that will enable the 
use of the AMDD (i.e. electricity, stable surface to place the dispenser on, and telephone 
access).
7. Able to be trained on the use of the AMDD.
8. Stable on at least two standard HF medications for at least one month.
Exclusion Criteria:
1. Life expectancy < 6 months.
2. Patients whose medications are already administered by family members or a  
caregiver.
Projected enrollment is 5-6 subjects a  month over nine months, for a  total of 50 subjects. 
nmnf.8t SMy fipwehret,
D.4. Data Collection.
D.4.a. Screening for Cl.
SLUMS will be used to screen for Cl and will be administered by HF clinic staff. The 
SLUMS exam is a  brief screening measure to a ssess  cognition.09,70 This 30-point, 11- 
item clinician-administered interview scale was developed by researchers at the St.
Louis VAMC and normed in a  veteran population. It contains norms adjusted for patient 
education levels, and quantifies the level of impairment as  none, mild, or impairment 
consistent with dementia, with the score of <27 considered to be consistent with Cl in a  
person with high school education or <25 in a  person with less than high school
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education. A comparison study of the SLUMS exam with the well-known Mini-Mental 
Status Examination [MMSE] in veterans suggested that the SLUMS exam was superior 
to MMSE in detecting mild Cl and impairment in executive functioning.71'74 
Trained research staff administered the SLUMS exam to 250 subjects in our prior study; 
all subjects were able to complete the test with an average time of completion of 7.1 
minutes (range 4-15). Similar to the MMSE, the SLUMS exam can also be administered 
by front-line clinicians. To demonstrate feasibility of screening using SLUMS in a  busy 
clinic setting with a  wide range of patients, we asked the RN and LVN staff in our clinic 
to use this tool to screen patients for Cl during the check-in process. The staff was 
trained in a  brief 15-minute insen/ice on how to accurately administer and score the 
SLUMS. The opportunity to administer the SLUMS exam was well received by the 
nursing staff; they noted that the time used to administer the SLUMS exam was 
equivalent to obtaining an accurate set of vital signs and checking VA clinical reminders. 
This exam was administered by the clinic nurses to 28 patients in an average of 7.2 
minutes over the course of one week.
D.4.b. Other data collection.
During the initial interview, we will collect basic demographic data, such a s  the patient’s  
gender, age, education level, living arrangement, and social support. Physical 
parameters collected at baseline and after the use of the AMDD include blood pressure 
(as m easured by a  standard manual cuff), heart rate (as m easured by direct auscultation 
of the heart with a  stethoscope), and weight (as measured by the sam e scale routinely 
used in the HF clinic). Clinical/functional data collected at baseline and after the use of 
the AMDD include NYHA class (as determined by a  health care practitioner from patient 
interview),2 BNP (standard lab test), and change in diuretic usage (determined by chart 
review).
D4.c. Quantitative data collection for feasibility.
As outlined in Aim 1, to test feasibility, we will m easure the percentage of patients 
qualifying for the AMDD (qualifying rate), consenting to participate (consent rate), able to 
place the AMDD in their homes and use it appropriately based on the instructions (user 
rate).
D.4.d. Qualitative data collection for feasibility.
Patient, family member and home health nurse interviews will be used to describe the 
reasons for not being able to use the AMDD, and patient satisfaction with the AMDD. 
These interviews will be qualitative in nature and conducted by the investigators using 
an interview guide designed to capture participant decision-making and identify barriers 
to use of the AMDD. The interview guide questions will cover four topics based on the 
MacCat-CR Interview format: understanding, appreciation, reasoning, and expressing a  
choice. Interview results will be analyzed using open and axial coding.73 We will also 
collect data on time spent to set up and fill the AMDD (average time per patient per 
month spent by the home health nurse).
D.5. Targeted intervention.
D.5.1. Baseline medication adherence.
Baseline MA to prescribed cardiac medications will be measured by a  30-day pill count. 
On study day one, subjects will bring in their medications for the initial pill count. They 
will continue with usual care, and return on study day 30 +/- 3 days for the baseline 30- 
day pill count.
D.5.2. Intervention with AMDD.
Only patients with MA <88% will continue with the AMDD part of the study, with the goal 
of 50 patients recruited to test AMDD. Based on data from our completed study, we 
estimate that we will need to recruit 80 subjects for the first pill count in order to arrive at
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the goal of 50 subjects with MA of <88%. We chose to test the AMDD only in subjects 
with baseline impaired MA in order to ensure the effect of the intervention in a  population 
that is most likely to benefit. Subjects selected to continue will be assigned the device to 
use for 60 days (one month to familiarize the study subjects with the device, one month 
to collect outcome data). The 30-day pill count will be repeated on study day 90.
D.6. Statistical Analysis.
Descriptive statistics include means, frequencies, variance, and simple correlations. To 
determine patients’ response to the AMDD, we will define patient-level and medication- 
level adherence rates by taking the absolute difference between the amount of pills 
prescribed and amount of pills taken, a s  shown:
with MA, a s  patient-level adherence for patient / over all cardiac medications, and MAV a s  
medication-level adherence for subject / and cardiac medication j=1 , ..., nb with P,j> 0 
pills prescribed and T#z 0 pills taken. This approach penalizes success whenever 
subjects either over-, or under-took a  prescription. All rates (qualifying, consent, user 
rates and “success” rates will be computed and tested for significance based on a  
binomial distribution, and by bootstrapping 10,000 samples. Mean AMDD response rates 
will be captured from the constant term to Generalized Linear Models (patient-level) and 
Generalized Estimating Equations (medication-level) with robust standard errors and 
logit linking function to account for repeated medication-level nesting within patient. For 
exploratory analyses, mean centered covariates may be added to adjust rates to 
account for differences in medication class, patient demographic (age, ethnicity/race), 
and clinical factors (Cl severity, illness duration).
Phone bank data from the centralized monitoring system will be used to establish and 
describe patterns of nonadherence (how many times did the patient need reminder calls; 
did the reminder calls have an identifiable pattern).
D.7. Power calculation.
Sample size power for n=50 was computed at 95% and 99% confidence intervals based 
on our pilot data (n=251) for three anticipated patient- and medication-level success 
rates and an estimated IntraClass Correlation = .414 with Cl 95%[.368, .457], 
F(1315,1315) a  2.410, p<.001, and mean 5.23 cardiac meds/patient (SD=1.808). 
Estimates were computed from 100,000 parametric bootstrapped samples simulating 
study condition for 50 completed subjects, a s  reported below in Table 1. In summary, we 
can detect a  20% clinically relevant success rate in patient-level adherence with a  two- 
tailed test a t an alpha=.05 with 99% power.
Table 1. Expected Confidence Intervals for Anticipated Success Rate for 50
Subjects.
MA,






12.5% 28.1% 39.6% 60.4% 71.9% 87.5%
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10.4% 31.3% 36.5% 63.5% 68.8% 89.6%
95% Confidence 
inten/ai
10.0% 32.0% 36.0% 64.0% 68.0% 90.0%
99% Confidence 
Interval
6.0% 36.0% 32.0% 68.0% 64.0% 94.0%
D.8, Data Management,
All data will be double entered and checked for consistency, with inconsistencies 
resolved by the study coordinator and principal investigator [PI]. Data are entered into 
secure electronic password-protected files residing in the VA in a  locked office, 
accessible only to approved study investigators and the study coordinator. To maintain 
patient privacy and confidentiality, data will be de-identified prior to statistical analysis by 
assigning subjects a  study number. A linkage log relating subject name and last four 
digits of their social security number to the study number will be kept in a  secure location 
in the HF clinic. After validation, de-identified data will be transferred to an SPSS format 
Research Ready file using our 3-part data accounting system designed to ensure data 
safety and security, ease  of access, information integrity, efficiency of use, and accuracy 
and consistency of data interpretation.76 All data will be processed on VA site, OI&T 
approved facilities through the VALLHCS Center for Advanced Statistics in Education.
D.9. Limitations,
The results of this study may not be generalizable to all patient groups with HF, 
specifically, nonveteran patients, women, or patients with clinically less severe HF who 
were not referred to HF clinic. Our study is limited by single center location, which may 
give rise to selection bias.
E. Research Context/Implementation Plan,
Contributing to the body of implementation science is an objective of the CHF QUERI s 
strategic plan, and in keeping with that objective, our research is designed to directly 
facilitate the implementation of evidence-based strategies known to improve outcomes in 
patients with HF. By addressing underlying Cl, the AMDD could produce reliable and 
persistent improvements in MA in a  population where traditional strategies have fallen 
short. This commercially available ‘off the shelf’ device, if found feasible, could be 
readily implemented into clinical practice to meet the immediate needs of the VA. 
However, in order for any novel intervention to be widely implemented by clinicians, 
effective case-finding to identify the population at risk is essential to improve outcomes 
and control costs. In order to identify cognitively impaired veterans more at risk for poor 
MA, a  simple yet reliable screening tool for Cl that can be used in clinical setting is of 
critical importance. We have shown that the SLUMS exam, which was developed by VA 
clinician/researchers and validated in a  veteran population, may be quickly and 
accurately administered by front-line staff in a  busy clinic setting. In addition, SLUMS 
provides a  cut-off score to identify mild Cl, which was shown to be sufficient to 
negatively impact MA in our pilot study.
The next goal will be to utilize results of this research to inform future studies examining 
whether early identification of, and intervention for, Cl in patients with HF will result in 
improved adherence and outcomes. The future trial would test implementation of a  
range of multidisciplinary interventions, including the AMDD for select populations. The 
study design would include methods to identify which patients are more likely to benefit 
from which intervention since the adherence may be moderated by presence of factors 
other than Cl. If future efforts show that targeted interventions are effective in improving
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outcomes in HF patients with Cl, it will provide impetus to implement screening for Cl in 
HF management guidelines, and potentially change the current standard of practice. 
Finally, this approach to patients with Cl is likely not unique to populations of patients 
with HF, and may be generalized to populations with other chronic illnesses, such as  
diabetes or hypertension. Thus we envision that the results from our studies examining 
patients with Cl and HF can be used in the future in other large veteran populations.
F. Barriers and Facilitators.
As a  feasibility study, our proposed research aims are designed to identify, both 
quantitatively and qualitatively, the practical issues that will need to be addressed during 
clinical implementation of the AMDD outside a  research context. Health care barriers in 
implementing the intervention with AMDD include cost of the device, time spent by 
clinical staff and the availability of home health nursing. Patient barriers include living 
situation, social and cultural issues, willingness to use the device, and lack of family 
support. Formal evaluation of these barriers is built into our study design. Future barriers 
in implementing the screening for Cl include time spent in clinic for screening, clinician 
aw areness and clinician “buy-in” (whether the clinician is convinced that screening for Cl 
will change the outcomes).
Formal analysis of direct and direct costs would be integral to future, larger trials; this 
pilot study will provide preliminary data about the costs of the intervention, a s  well a s  
unforeseen barriers.
Possible facilitators to overcome barriers include seeking support of local and national 
VA administrators, enlisting local opinion leaders in raising clinicians’ aw areness of the 
problem, and familiarizing the clinicians with the data as  outlined in the dissemination 
plan.
G. Evaluation olan/Plseemlnatlon.
We will evaluate the results of this study in light of published data prior to dissemination. 
Rogers’ Diffusion of Innovation Theory suggests that new ideas are spread by 
individuals, largely by imitation.1,77 We will utilize local opinion leaders at our facility a s  
well a s  the CHF QUERI network to disseminate results of this pilot study. The results of 
this pilot trial will be presented at national cardiology meetings and published on the 
QUERI website. We also expect to publish a  manuscript with the findings in a  peer- 
reviewed cardiology journal to ensure wider dissemination of the data.
H. Project Management Plan.
H.1. Study Timeline.
Table 2. Gantt Chart for study timeline.
Activity Month
1
Month 2-7 Month 8-10 Month 11- 
12
Preparation and submission 
of documents to IRB
Hire/train study coordinator ----------







Write final report —
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H.2. Resources Required.
This is a  single center study and will be conducted at VALLHCS, utilizing existing space 
in the cardiology and research sections. The PI and co-PIs will have access to statistical 
resources and the library at the VALLHCS and at Loma Linda University.
The Philips medication dispenser will be contracted at the regular market rate of $85.00 
for installation, and $75.00 per month for monitoring. We will not enter into any special 
financial arrangement with the Philips company to avoid financial conflict of interest, and 
to allow us to retain ownership of all data collected.
H.3. Research Team.
The project team is multidisciplinary and includes:
Principal Investigator (Name removed) MD. MPH is currently working a s  a  staff 
cardiologist at VALLHCS. (Name removed) has been active in cardiology outcomes 
research with special interest in patients with atrial fibrillation and HF. As PI, she will be 
responsible for the study and will coordinate the work among the co-investigators and 
the study coordinator. She will oversee all the aspects of the study, including the 
regulatory aspects, patient recruitment, and adherence to the proper consent process, 
data collection and data management. She will be responsible for analyzing and 
interpreting the results of the study with the project team.
Co-lnvestiaator Lee Ann Hawkins. RN. MSN. FNP is the HF Clinic nurse practitioner at 
the VALLHCS. She is pursuing her PhD and is active in HF research. As co­
investigator, she will be responsible for the day-to-day aspects of the study, training the 
study coordinator and working closely with him or her to ensure that operations are 
performed according to schedule and according to study protocol. She will also fill in for 
the PI responsibilities when the PI is on vacation or not available.
Co-Investigator and Senior Research Consultant (Name removed). PhD is a  Research 
Professor of Medicine at the Loma Linda University School of Medicine and Director of 
the Center for Advanced Statistics in Education at the VALLHCS. He is a  well-published 
senior HSRD career scientist who will be involved in the design and analysis part of the 
study. As co-investigator, he will serve in an advisory capacity, based on his prior 
experience in multivariable analysis in numerous HSR&D research projects. 
Co-lnvestiaator and Senior Research Consultant (Name removed). MD. MS is currently 
the director of Diabetes Services at the VALLHCS. He has been PI or co-PI on 
numerous research projects. As co-investigator, he will serve in an advisory capacity, 
based on his prior experience in chronic diseases outcomes research.
Co-investiaator (Name removed!, PhD is a  Neuropsychologist who conducts 
neuropsychological assessm ents for a  variety of patients with cognitive disorders at 
VALLHCS and has prior research experience in the a rea of Cl. She will serve in an 
advisory capacity to help interpret the results of this study and design future studies. 
Study Staff. (Name removed). PharmP is currently working a s  the Research Pharmacist 
and Infectious Disease Clinical Pharmacist at the VALLHCS. He will serve in an advisory 
capacity in collecting and interpreting the pill count data.
The study coordinator will be hired prior to the start of the study. He or she will be 
responsible for screening potentially eligible patients for the study, collecting study data, 
coordinating the setup of the AMDD with the Philips company and with the home health 
nurse, coordinating and conducting appointments for labwork and performing pill counts. 
The study coordinator will receive alerted telephone calls from the Philips central 
monitoring station, and initiate calls to the subjects a s  appropriate. The study coordinator 
will also perform chart review with the supervision of the PI and co-PIs, assist with
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preparation and maintenance of all regulatory documentation, and enter all clinical data 
to Excel database.
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Background: Interventions to increase medication adherence are needed to improve 
heart failure (HF) outcomes. A recently completed study tested a pictorial medication 
sheet to improve adherence in veterans with HF and cognitive impairment. While health 
literacy (HL) scores were not collected as part of that study, they were part of the patient 
medical records. This new data-based study examines potential mediating effects of HL 
on observed medication adherence in that study.
Objectives: (a) describe the level of HL, (b) determine relationships between HL and 
selected clinical and demographic variables, and (c) estimate the relationships between 
HL, key variables, and medication adherence in the study sample.
Methods: In a secondary analysis, HL scores from medical records were analyzed with 
data from the original pilot study using conventional statistics and structural equation 
modeling.
.Results: 27 subjects with a mean age of 65.3 years (SD 8.2, range 45-80) had evaluable 
data. HL was less than adequate in 19% of the sample. HL scores were strongly 
correlated with cognition. HL did not significantly affect relationships between study 
covariates (cognition scores, depression, number of medications) and medication 
adherence.
Conclusions: HL scores are associated with cognitive function scores. More research is 
needed to evaluate the prevalence and effect of poor HL on medication adherence in 
veterans with HF.







IRB: Institutional Review Board
NYHA: New York Heart Association
RMSEA: Root Mean Square Error of Approximation
SEM: Structural equation modeling
SLUMS exam: Saint Louis University Mental Status examination 
VA: Veteran’s Health Care Administration
Introduction
Heart failure (HF) is an epidemic confronting the American healthcare system; 
currently 5.8 million people in the United States have HF, and this number is projected to 
grow as the population ages.1'3 HF presents as a complex chronic disease characterized 
by frequent exacerbations often resulting in emergency department visits and hospital 
readmissions. This excessive admission-readmission cycle is costly in terms of poor 
patient outcomes as well as healthcare expenditures, particularly within the Veterans’ 
Health Care System (VA), the largest integrated healthcare system in the United States. 
Within the VA, 20% of HF patients are readmitted within 30 days, contributing to the 
total annual cost estimates of over $37 billion for HF care in the United States.4 The 
majority of HF readmissions are related to medication non-adherence and are therefore 
preventable.3'9 Thus identification of and intervention for factors contributing to poor 
medication adherence is key to reducing readmissions and improving outcomes.10,11
Factors related to poor medication adherence
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Adherence is a complex issue and may be conceptualized as one of the dynamic 
and multidimensional activities that comprise self-care. Self-care is particularly important 
in a chronic illness such as HF that is primarily managed at home by the patient him or 
herself. Conceptual frameworks and theoretical models describe HF self-care as an
19 1 ̂
iterative process requiring a series of thoughtful decisions on the part of the patient. ’ 
Factors that affect decision making such as difficulty in understanding and remembering 
directions, or the presence of depression, impair the patient’s ability to engage in 
successful self-care.12,13 The capability to make appropriate decisions is especially 
critical in negotiating the complex medication regimen HF patients are often required to 
follow. Because HF is primarily a disease of the elderly and presents with co-morbid 
illnesses, this complexity is compounded by polypharmacy prescribed by multiple 
providers, and the fact medications are subject to change with each hospital 
readmission.8,2
One important, yet clinically under-recognized factor affecting a patient’s ability 
to correctly take medication is the presence of cognitive impairment (Cl)- It is clinically 
intuitive that impairment in cognitive domains such as memory, verbal fluency, attention, 
motor speed, and executive functioning (e.g. higher-order capacities such as planning and 
problem-solving) would negatively affect a person’s ability to correctly obtain and take 
medications.14,15 Cl has been shown to be a prevalent co-morbid condition in outpatients 
with HF, who may have a four-fold risk of developing Cl compared to the general 
population.15'17 A recent study of outpatient veterans with HF demonstrated a high 
prevalence (58%, n=251) of clinically unrecognized Cl that was significantly associated 
with poorer medication adherence.14
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Another factor commonly associated with non-adherence to medication is poor 
health literacy (HL), broadly defined as the degree to which individuals obtain and 
understand basic information in order to make appropriate decisions and negotiate the
1 flhealthcare system to manage their well-being. In America, low HL is considered to be a 
prevalent and clinically under-recognized problem in the general population; up to 57% 
of patients with HF may have poor HL.18'21 One study assessed HL in 1,786 veterans 
and reported a lower prevalence of poor HL than is generally described in the civilian 
population; specifically 8.3% of subjects had inadequate and 11.8% had marginal HL 
skills.22 However, little is known about the prevalence of poor HL in veterans with HF, or 
the effect of HL on medication adherence in cognitively impaired veterans with HF.
Depression is yet another condition that has been associated with less than 
adequate self-care, and worsened outcomes such as hospital readmissions and mortality, 
in persons with HF.23,24 Studies have shown depression to be common in persons with 
HF, with prevalence rates conservatively estimated at about 26%, or 2 to 3 times higher 
than in the general population.24 Although examining the effect of depression on HF 
outcomes has received increasing attention in the literature, this condition often remains 
clinically under-recognized. 23,24 For example, in a study of 250 veterans with HF, the 
average subject was found to be mildly depressed, yet only 30% of the sample had been 
formally diagnosed.14
Interventions to Improve Adherence
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Unfortunately there remains a general lack of awareness on the part of providers, 
as well as no incentive in the current model of healthcare, to screen elderly HF patients at 
risk for poor medication adherence at clinic visits.23,26 Interventions to improve 
adherence that rely on traditional models of patient education are likely to fail in this 
population. There is a paucity of tested interventions designed to improve outcomes by 
targeting key determinants of poor adherence such as Cl and poor HL.23’27 Interventions 
that have shown improvement in adherence to date were complex and did not result in 
sustainable outcomes.28'30
Cognitive impairments such as impaired memory and verbal fluency are 
associated with poor HL and are commonly found in elderly persons with HF. Indeed, 
the close association of poor HL with Cl has received increased attention in the literature; 
a recent study proposed that current measures of HL are actually rudimentary 
assessments of cognition.32 Hence, interventions to improve adherence in patients with 
low HL should also reduce demands on cognitive abilities. The commonly accepted view 
that simply utilizing S^-grade language and a few illustrations for health information will 
not help low-literacy patients if the pictures must be mentally integrated to be 
understood.19,28
As a first step to address this gap, a pilot study (TARGET) was designed to target 
Cl as an underlying cause of medication non-adherence. The TARGET study enrolled 36 
subjects with known Cl from an outpatient veteran HF clinic and tested the effectiveness 
of a customized pictorial medication sheet along with an optional alarmed pillbox to 
improve medication adherence.33 The primary outcome, medication adherence, was 
measured from sequential direct 30-day pill counts, using subjects as their own controls.
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Secondary outcomes included feasibility and tolerability determined by qualitative 
interviews.
A major limitation in the TARGET study was that no information on HL was 
collected as part of the study itself. HL may actually have mediated the relationship 
between key independent variables (including the intervention) and the outcome measure 
of medication adherence.
Therefore the purpose of this study was to estimate the relationships between 
participant’s HL scores (obtained from the medical record), and key variables, including 
the outcome, medication adherence, using data obtained from the TARGET study.
The specific aims of this study included:
Aim 1. Describe the level of HL in the study population.
Aim 2. Determine the strength and direction of relationships between HL and selected 
clinical and demographic variables in the study population.
Aim 3. Determine the direct and indirect effects that HL and other key variables 
(including the intervention) on post intervention medication adherence in cognitively 
impaired veteran outpatients with HF.
Methods
The study employed a retrospective, correlational, cross-sectional design using 
data from the completed TARGET pilot study and the participants’ medical records. 
Approval was obtained from the institutional review board (IRB) prior to data collection. 
The data were de-identified prior to analysis. The TARGET study was conducted at a 
large metropolitan Veteran’s Administration facility that serves an urban population of 
246,000 veterans in southern California.
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Sampling Procedure
The sample included subjects (n=36) from the TARGET pilot study. These 
subjects were originally recruited as a convenience sample from an outpatient VA 
medical center HF clinic between November 2011 and June 2012. All were 18 years old 
or older, had an established clinical diagnosis of HF, and had screened positive for Cl 
using the Saint Louis University Mental Status (SLUMS) exam34 prior to entrance into 
the study. SLUMS is an education-adjusted, 30-point clinician-administered screen for Cl 
that has been validated in a veteran population and shown to be more sensitive to 
detecting mild Cl than the more familiar MMSE.35,36
In order to participate in testing the pictorial medication sheet and alarmed 
pillbox, participants were required to speak and read English, follow simple directions, be 
able to see, and have the manual dexterity to take their own medications. Thus, persons 
with severe functional limitations, acutely decompensated HF, dementia requiring a 
caregiver, or severe mental illness, such as active schizophrenia, were excluded. Subjects 
were also excluded if they had a life expectancy of less than six months. The TARGET 
study was designed as a pilot study to test feasibility and effectiveness of the 
intervention. Thus, no power analysis was conducted.
Data Collection Procedures
For this current study, subject’s data were retrospectively obtained from the 
TARGET study data and the electronic medical record, and placed into a database with 
all personal identifiers removed. This database was compiled by the investigator and 
audited for completeness and veracity by another researcher. The new database included 
HL scores from the subject’s medical record and medication adherence scores,
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demographic, and clinical data from the TARGET study. Demographic data included age, 
gender, race, living arrangements (alone or with others), and educational level. Clinical 
data included the presence of comorbid depression, participant’s SLUMS score, and 
number of prescribed medications. These demographic and clinical data were selected as 
having potential influence on medication adherence in the study sample, based on 
review of relevant literature. Subject ID numbers were assigned sequentially, and all data 
was subsequently de-identified.
Details of the TARGET study have been reported elsewhere, but are summarized 
here for relevance to the current investigation.33 The TARGET study consisted of four 
study visits. Subjects were enrolled during a routine visit to the investigator’s clinic. At 
study visit one, subjects were asked to bring in all their regularly prescribed medications 
for a pill count. Subjects returned in approximately 30 days for visit two. At visit two, a 
repeat pill count was performed to determine baseline adherence. During this visit the 
subject received a customized pictorial medication sheet consisting of images of their 
current medications in full color and dose range (i.e. the image showed two and one-half 
tablets if they were to take two and one-half tablets) in columns for morning, noon, and 
evening. Brief descriptions of the medication name, indication and dose were also 
included. A sample medication sheet is displayed in Figure 1. Subjects were also offered 
an optional CADEX Pocket Pill Box (ePill LLC) with 4 vibrating daily alarms. Subjects 
returned for repeat 30-day pill counts at visit three (giving them a month to adjust to the 
intervention), and visit four, to determine their post-intervention adherence. At each visit 
the subject had a brief physical exam and New York Heart Association (NYHA) 
functional class determined by the investigator. Qualitative data regarding the feasibility
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and acceptability of the intervention were collected in patient interviews at each visit 
using standardized questions.
Measures
In the current study, data related to HL were derived from participants’ scores on 
the Short Test of Functional Health Literacy for Adults (S-TOFHLA) documented in the 
medical record.37 This instrument was derived from the longer Test of Functional Health 
Literacy for Adults (TOFHLA) designed to assess the ability to perform basic reading 
and numerical tasks in a healthcare setting.38 The S-TOFHLA has been shown to be 
valid, reliable, and easily administered in a clinical setting.37 The S-TOFHLA includes a 
timed (7 minute) reading comprehension test using the modified Cloze procedure; the 
patient reads common medical instructions that have every 5th to 7th word in a passage 
omitted and is asked to select a word from 4 multiple-choice options to fill in the blank 
spaces. Possible scores range from 0-36, with 0-16 scored as “inadequate”, 17-22 
“marginal” and 22-36 “adequate” health literacy37’38 In addition, the S-TOFHLA 
includes a 17-item, timed (10 minute) numeracy subscale that tests the practical ability of 
patients to comprehend medication prescription labels, results of blood glucose tests, 
clinic appointment slips, and financial assistance for healthcare information. The 
numeracy subscale is scored in a weighted manner according to the test manual to create 
a final score ranging from 0-50.38 These HL measures had been administered to patients 
in the HF clinic as part of usual care since January 2011, and scores recorded on progress 
notes maintained in the VA electronic medical record. There is no evidence in the 
literature that HL scores as assessed by S-TOFHLA change over time.
As background, the data on the dependent variable for this study, medication 
adherence score, was obtained for each prior study subject from their post-intervention 
30-day pill count collected as part of the prior TARGET study. The TARGET study 
medication adherence scores were determined in the following manner: to capture both 
overtaking and undertaking medication, a delta was determined for each prescribed 
medication by computing the absolute difference between the number of pills taken 
versus the prescribed number over the 30-day period for each pill count. The delta values 
for each medication were summed for each individual subject, divided by the total 
number of pills prescribed, subtracted from 1, and finally multiplied by 100 to obtain an 
adherence score expressed as a percentage. Thus, a value of 100% indicated all pills were 
taken correctly. A value of 85% meant that 15% of prescribed pills were either not taken, 
or overtaken, or a combination of both. All currently prescribed medications were 
included in the pill counts, except medications taken on an “as needed” (pm) basis, 
injectables, and inhaled medications. Over-the-counter medications were also excluded. 
Statistical Analysis
Data analysis was performed using Statistical Package for the Social Sciences v. 
20 (SPSS) (IBM Corporation) and Mplus v.7 software (Afplus, 2012). A p-value of .05 or 
less was determined as significant. Frequency distributions for each variable were 
examined for normal distribution characteristics, missing data, and outliers.
Descriptive statistics, including measures of central tendency and frequency, were 
employed to address study aim one. Study aim two was explored using bivariate 
correlational tests appropriate to the level of measurement (e.g. Spearman’s rho for 
ordinal data and Pearson’s r  for interval or ratio level data). To achieve aim three,
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structural equation modeling (SEM), specifically a path mediation model, was utilized for 
analysis.
Results
Study characteristics. Thirty-six (36) subjects were enrolled in the TARGET 
study. Of these, two subjects died before completing the study; one subject was 
hospitalized for a prolonged period and was not able to return in a timely manner for 
study visits; one subject dropped out due to transportation issues; three subjects had 
unusable adherence data (they attended all study visits but did not bring in medication 
consistently enough to be counted); and two simply did not return for scheduled study 
visits despite repeated telephone and written messages asking them to do so. Thus, 27 
subjects completed the study with usable data; 26 (96%) were male, with an average age 
of 65.3 years (SD 8.2, range 45-80). Baseline characteristics of the study sample are 
presented in Table 1.
Prevalence of poor HL. The mean reading HL (S-TOFHLA) score for the sample 
was 29.92 (n=26, SD 7.27, range: 15-36) and the mean numeracy HL score was 43.40 
(n=27, SD 9.36, range 15-50). Specifically, 19.2% of the entire sample had less than 
adequate HL (S-TOFHLA score <23). Only one subject did not complete the reading HL 
instrument and therefore this was treated as missing data with no imputations for the 
analysis.
Correlational analysis. The strength and direction of relationships between 
reading HL, numeracy HL, and demographic and clinical variables were explored as 
shown in Table 2. Few significant relationships were found in this study. Specifically, 
age was negatively associated to both reading HL (r = -.407, p < .05) and numeracy HL
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(r = -.499, p  < .05). This suggests a moderate contribution of age to the variability in HL 
scores (lvalues of .16 and .25, respectively). SLUMS exam scores were strongly 
associated with both reading HL (r = .804, p < .01) and numeracy HL (r = .545, p  c.Ol). 
This suggests a moderate to strong contribution of cognition to the variability of health 
literacy scores values of .65 and .30, respectively).
Structural equation model. A path mediation model was constructed after a set of 
preliminary analyses including descriptive data examination for outliers, missing data and 
non-normality were conducted. Three exogenous covariates chosen for the model were 
based on review of relevant literature and included SLUMS score, number of prescribed 
medications, and history of depression. Reading and numeracy HL scores were 
hypothesized to mediate the effects of the covariates on the dependent endogenous 
variable, medication adherence.
Analysis of post-intervention data using the path model revealed that path 
coefficients were in the hypothesized direction. SLUMS score was associated with 
reading HL (standardized coefficient 4.995, p -  0.000) and numeracy HL (standardized 
coefficient 3.842, p  = 0.000); history of depression was negatively associated with 
numeracy HL (standardized coefficient -2.513, p = 0.012); and the number of prescribed 
medications had a direct, negative association with medication adherence (standardized 
coefficient -2.515, p -  0.012). Model fit was evaluated and found to be acceptable by 
Chi-square (0.755, df 1, p  = 0.385) and a Root Mean Square Error of Approximation 
(RMSEA) estimate of 0.000,90% Cl 0.000 -0.473, and probability of RMSEA <= .05: 
0.430. The path model is presented in Figure 2.
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An attractive aspect of path modeling is the ability to estimate indirect, or 
mediating, effects as well as direct and total effects among variables. In relation to study 
aim number three, Table 3 presents the estimated indirect effects of HL scores for the 
covariates on post-intervention medication adherence. Neither reading nor numeracy HL 
scores reached statistical significance as mediating the effects of SLUMS score ip =
0.459 and 0.604, respectively), history of depression (p = 0.862 and 0.608, respectively), 
or number of medications ip = 0.575 and 0.716, respectively) on medication adherence. 
Discussion
This study had three important findings: (1) The prevalence of poor HL in the 
study sample was lower than generally described in the civilian population, (2) cognitive 
function was strongly correlated with measures of HL, and (3) HL did not mediate the 
outcome of medication adherence in the interventional TARGET pilot study.
We found HL to be less than adequate in 19% of our study sample, which is 
strikingly similar to the 20% reported by Griffin in a study of over 1700 veterans (not 
limited to those with HF).22 Poor HL in the general population with HF has been 
reported to be as high as 57%.21 Further study is warranted to better understand the 
prevalence of poor HL in veterans with HF.
Our finding that the subjects’ cognitive scores strongly correlated with HL scores 
is supported by current trends in the literature. For example, the cognitive domains of 
memory and verbal fluency were related to HL in a study of 414 older community- 
dwelling adults.31 Intriguingly, these two domains were found to be the most affected in 
a study of veterans with HF and Cl.14 In the LitCog study (n=882), associations between 
poor HL and performance of healthcare tasks diminished once cognitive ability was
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controlled for, and the authors concluded that measures of HL actually identified 
differences in cognition.32 This study is one of the first to examine the effect of HL on an 
intervention to improve adherence that was modified to address patient’s cognitive 
limitations.
The finding that HL did not mediate the effect of the covariates Cl, depression, 
and number of medications, on medication adherence in the TARGET study is not 
surprising for several reasons. Foremost, the TARGET interventional medication sheet 
was not specifically designed to address poor HL, although it does incorporate 
medication images with simple text. Next, the low prevalence of poor HL in the study 
sample may have affected the outcome. Finally, there may be covariates other than the 
three chosen for analysis that may have had a stronger interaction with poor HL. 
Implications for Practice
It is important for clinicians to identify those patients at risk for poor medication 
adherence so that extra resources may be allocated to help them. This risk profile will 
need to be tailored to individual patient populations, and include screening for prevalent 
conditions that have been shown to contribute to poor adherence in that particular 
population. For the busy clinician screening HF patients for Cl and depression may have 
better yield than trying to screen for poor HL. The design of future interventions to 
improve adherence should take into account all the cognitive demands placed on the 
patient rather than simply skills in reading and numeracy.
Strengths and Limitations of Methods
There are important limitations to this research design. The sample size is small, 
drawn from a pilot feasibility study, and was selected as a convenience sample from the
investigator’s HF population of predominantly elderly Caucasian male veterans from an 
urban southern California VA medical center. The VA system offers ready access to 
prescription medication coverage. Therefore, the results may not be readily generalized to 
other populations. There is no data available to know if HL scores obtained from the S- 
TOFHLA instrument and recorded in the past medical record would change over time. 
Finally, the study sample size was theoretically inadequate for full SEM analysis. 
Although not a panacea for low sample size, the bootstrapping option (as was done in this 
study) may be employed for exploratory analysis. Indeed, we did run our path analysis 
with an additional 500 bootstrapping sample iterations, and did not fmd substantial 
differences in the significance testing.
Conclusions
Consistent with the current literature, the prevalence of poor HL in our sample 
population of veterans with HF and Cl was lower than generally found in the civilian 
population; and HL scores were found to be strongly associated with cognitive function 
scores. HL did not mediate the effect of key variables on the outcome, medication 
adherence. More research is needed to evaluate the prevalence and effect of poor HL 
upon adherence in veterans with HF and Cl.
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Table 1. Characteristics of the Study Sample.
76
Variable Subjects n=27







Less than high school 4 (14.8%)
High school diploma 9 (33.3%)
College or above 14 (51.9%)
Living arrangements:
Alone 11(40.7%)
With others 16 (59.3%)
History of depression 13 (48.1%)
SLUMS score1 mean ± SD (range) 22.90 ±2.93 (13-26)
Number of prescribed med.
mean ± SD (range) 14.44 ±5.93 (5-27)
Med: medication, SD:
standard deviation, SLUMS: Saint Louis University Mental Status exam, S-TOFHLA: Short form test of 
functional health literacy for adults.
1 SLUMS screening is positive for mild cognitive impairment for score < 27 in persons with high school 
diploma or <25 in persons who did not complete high school. Screen is considered positive for severe 
impairment consistent with dementia for score <21 for persons with high school diploma or <20 for persons 
who did not complete high school.
2 S-TOFHLA is scored from 0-36, with 0-16 considered inadequate, 17-22 marginal, and 22-36 adequate 
health literacy.
3 Numeracy is scored from 0-50.
4 Prescribed medications for the participant at the start of study, obtained from chart review.
Table 2.






Pearson Correlation -.407 -.499










Sig. (2-tailed) .437 .109
SLUMS Score1
Pearson Correlation .804 .545
Sig. (2-tailed) .000 .003
Depression
Point-biserial -.106 -.218
Sig. (2-tailed) .607 .276
# Medications2
Pearson Correlation .205 .007
Sig. (2-tailed) .127 .971
Adherence Pre3
Pearson Correlation -.210 .070
Sig. (2-tailed) .303 .730
Adherence Post4
Pearson Correlation -.046 .085
Sig. (2-tailed) .825 .674
Saint Louis University Mental Status exam
2 Number of prescribed medications for each subject
3 Medication adherence pre-intervention in TARGET pilot study
4 Medication adherence post-intervention in TARGET pilot study
Table 3.
Indirect Effects of HL Scores on Medication Adherence
HL did not mediate the effect of cognitive impairment, depression, or number of
medications on medication adherence after exposure of the subjects to the intervention.
Reading HL Score Indirect effect 
post-intervention1 ’2
Two-tailed P-value
SLUMS score -0.121 0.459
History of depression 0.005 0.862
Number of medications -0.022 0.575
Numeracy HL Score
SLUMS score 0.065 0.604
History of depression -0.046 0.608
Number of medications 0.009 0.716
1 Estimated regression coefficient for indirect effect
2 Standardized (Z-score)
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Two, once a day 
Heart
Furosemlde 40mg
One, once a day 
Water B
Valsartan 160mg








TWo, 3x per day 
Neuropathy pain B B H
Tamsulosln
0.4mg










viodel fit: Chi-square (0.755, df 1, p = 0.385); Root Mean Square Error of Approximation (RMSEA) 
estimate of 0.000,90% Cl 0.000 -0.473, and probability of RMSEA <= .05:0.430.
Figure 1. Three exogenous covariates are shown in the boxes on the left; slums = Saint 
Louis University Mental Status Exam (cognitive scores); hxdep =history of depression as 
determined by chart review; nummedsp =number of medications prescribed for each 
subject at the start of the study. Health literacy scores are shown as the mediating 
variables in the boxes in the middle of the model: stofhla =Short Test of Functional 
Health Literacy for Adults (reading HL), and Numeracy (numeracy HL). The endogenous 
dependent variable is shown in the box to the far right: adallp =post-intervention 
medication adherence. The numbers on the paths represent unstandardized regression 
coefficients with standard errors in parenthesis.
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Dissertation Summary and Conclusion
This dissertation presented elements of my program of research in the field of 
medication adherence, cognition, and health literacy in persons with heart failure (HF). 
The overarching goal of this research is to improve HF outcomes by effecting change in 
the current model of care by ensuring patients at risk for poor medication adherence are 
identified and given extra support and assistance.
The background, review of the current literature, and theoretical framework 
relative to this research was included in Chapters 1 and 2. Chapter 3 presented the 
methodology for the study protocol that was proposed and conducted as the focus of this 
dissertation.
The three research papers contained in this dissertation represent the natural flow 
of a developing program of research. Initially, based on a problem noted in clinical 
practice, research was conducted that revealed unrecognized cognitive impairment that 
significantly worsened medication adherence in a sample of veterans with HF. This is 
reported in the first manuscript, Cognitive Impairment (Cl) and Medication Adherence in 
Outpatients with Heart Failure, which has been accepted for publication (Hawkins, 2012). 
The results of that research informed the next two papers. The second document is a grant 
proposal: Targeted Intervention of Improve Medication Adherence in Cognitively 
Impaired Patients with Heart Failure. This is a project to test the feasibility and 
effectiveness of an automated medication-dispensing device to help patients with HF and 
Cl take their medications correctly at home. The grant was funded and enrollment began 
November 2012. The final paper presents the results in manuscript form of the protocol
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described in Chapter 3: Health Literacy and Use of a Pictorial Medication Sheet to 
Improve Adherence.
These research efforts have added to the body of existing nursing knowledge, and 
will provide a foundation for a continuing program of research. The Veterans 
Administration has compiled a library of 30,000 medication images, however the use of a 
pictorial medication sheet has not been tested in the veteran population (Echt, McConnell 
& Trettin, 2012). This dissertation research is one of the first to examine the effect of HL 
on a pictorial intervention to improve adherence in veterans with HF and Cl. In addition, 
testing an intervention targeted towards underlying Cl and poor HL operationalizes the 
Self-Care of HF model (Riegel, 2008) in a unique way.
Conclusion
It is important for clinicians to identify those patients at risk for poor medication 
adherence so that extra resources may be allocated to help them. This risk profile will 
need to be tailored to individual patient populations, and include screening for prevalent 
conditions that have been shown to contribute to poor adherence in that particular 
population. For the busy clinician screening HF patients for Cl and depression may have 
better yield than trying to screen for poor HL. The design of future interventions to 
improve adherence should take into account all the cognitive demands placed on the 
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